Therapeutic agent composition
Novel thalidomide derivatives with reduced proteolytic activity for SALL4 and PLZF address teratogenic risks in cancer treatment, ensuring effective cancer therapy with minimized birth defects.
Patent Information
- Application Number
- JP2024165038
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-27
- Filing Date
- 2024-09-24
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2042-10-27
AI Technical Summary
Thalidomide and its derivatives, despite their effectiveness in treating blood cancers, pose significant teratogenic risks due to their ability to degrade proteins like SALL4 and PLZF, leading to severe birth defects.
Development of novel target protein degradation-inducing compounds, specifically thalidomide derivatives with reduced proteolytic ability for SALL4 and PLZF, formulated as 'Cereblon binder' - 'linker' - 'target protein binder' compositions, including compounds like F-lenalidomide and JQ-1, to induce targeted protein degradation in cancer treatment while minimizing teratogenicity.
These compounds effectively degrade cancer-related proteins without significantly degrading SALL4 and PLZF, thereby reducing teratogenicity and maintaining therapeutic efficacy against cancers such as multiple myeloma and myelodysplastic syndrome.
Smart Images

Figure 2024169626000073 
Figure 2024169626000074 
Figure 2024169626000075
Abstract
Description
[Technical field]
[0001] The present invention relates to a therapeutic composition, in particular a novel target protein degradation-inducing compound, a cancer therapeutic composition containing said compound, and more particularly a cancer therapeutic composition which avoids teratogenicity. This application claims priority to Japanese Application No. 2021-175996, which is incorporated herein by reference. [Background technology]
[0002] (Thalidomide drug damage) Thalidomide is a drug that was used worldwide as a sleep-inducing drug for pregnant women more than half a century ago. However, it caused serious teratogenic effects on the limbs of fetuses born to pregnant women who had taken the drug, resulting in a worldwide drug-related problem known as the thalidomide disaster. However, thalidomide has been shown to be effective against leprosy and multiple myeloma, and currently, thalidomide and its derivatives (lenalidomide and pomalidomide) are highly effective drugs that are used annually under strict safety management as treatments for blood cancers such as multiple myeloma, at a cost of approximately 1 trillion yen. It has been shown that thalidomide and its derivatives (immunomodulatory drugs / IMiDs) induce the degradation of various proteins by binding to cereblon (CRBN), a component of the E3 ubiquitin ligase, a proteolytic enzyme, resulting in a variety of pharmacological actions and side effects.
[0003] It has been reported that SALL4 (Sal-like protein 4), a protein that plays an important role in fetal limb development, is induced to degrade by CRBN in an IMiD-dependent manner. Recently, the present inventors have clarified, through structural analysis, the mechanism by which a hydroxylated form (5-hydroxythalidomide), which is generated by metabolism of thalidomide in the body, acts on SALL4 more efficiently than thalidomide itself (see Non-Patent Document 1). However, many aspects of the mechanism of teratogenicity caused by thalidomide and its derivatives remain unclear, and the existence of causative proteins other than SALL4 has been suggested.
[0004] (Targeted protein degradation inducer compound) PROTACs (Proteolysis Targeting Chimeras) are small molecule compounds that utilize the ubiquitin proteasome system (UPS) to induce degradation of targeted proteins (Targeted Protein Degradation, TPD) in cells (see Non-Patent Document 2). A target protein decomposition inducer compound (PROTAC compound) forms a ternary complex by binding an E3 ubiquitin ligase and a target protein. This formation causes the target to be polyubiquitinated and degraded by the proteasome. The target protein decomposition inducer compound detaches from the complex after the polyubiquitination reaction and acts catalytically by repeatedly binding to a new target and an E3 ligase. This catalytic action causes the target protein to be depleted by proteasome digestion after ubiquitination in the cell, leading to cell death, and is effective against various diseases (e.g., cancer).
[0005] (Prior Patent) Patent Document 1 discloses "a pharmaceutical composition comprising 6-hydroxylenalidomide, a salt thereof, or a solvate thereof." Patent Document 2 discloses "imide-based proteolysis modulators." However, these documents do not disclose or suggest the target protein degradation-inducing compounds of the present invention. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] Patent Publication No. 2021-20873 [Patent Document 2] Special Publication No. 2017-513862 [Non-patent literature]
[0007] [Non-Patent Document 1] (2020) Structural bases of IMiDselectivity that emerges by 5-hydroxythalidomide Nat Commun 11: 4578 [Non-Patent Document 2] https: / / www.funakoshi.co.jp / contents / 63923 Summary of the Invention [Problem to be solved by the invention]
[0008] The present inventors have identified a new protein involved in thalidomide teratogenicity, promyelocytic leukemia zinc finger (PLZF), and have elucidated the molecular mechanism of thalidomide teratogenicity and the CRBN-dependent degradation of PLZF by thalidomide, its derivatives, and 5-hydroxythalidomide. In addition, the present inventors performed a gene knockdown experiment of PLZF in chicken embryos, an animal species sensitive to thalidomide, and confirmed that PLZF plays an important role in the development of chicken embryo limbs. Furthermore, the administration of thalidomide or 5-hydroxythalidomide to chicken embryos reduced PLZF, but not SALL4, in the limb buds of chicken embryos. In addition, the inventors have demonstrated that overexpression of PLZF in chicken embryos restores the reduced expression of fibroblast growth factors Fgf8 and Fgf10 induced by thalidomide administration. These results confirmed that thalidomide-dependent degradation of PLZF by CRBN is directly involved in thalidomide teratogenicity, and that in mammalian species highly sensitive to thalidomide, such as humans, monkeys, and rabbits, thalidomide is metabolized to 5-hydroxythalidomide by metabolic enzymes in the body and that severe teratogenicity is caused by the degradation of both SALL4 and PLZF proteins. Therefore, an objective of the present invention is to provide a novel target protein degradation-inducing compound, a cancer therapeutic composition containing said compound, in particular a cancer therapeutic composition that does not cause severe teratogenicity. [Means for solving the problem]
[0009] Based on the above finding that a thalidomide derivative that reduces the degradation of both SALL4 and PLZF proteins serves as an E3 ligase binder for a target protein decomposition-inducing compound that can avoid severe teratogenicity, the present inventors have discovered a thalidomide derivative that reduces the decomposition ability of both SALL4 and PLZF proteins, and further confirmed that a target protein decomposition-inducing compound containing said derivative has an anti-cancer effect, thereby completing the present invention. That is, the present invention is as follows.
[0010] 1. A target protein degradation inducer compound having the following composition: "Cerebron binder" - "linker" - "target protein binder", Here, the cerebron binder is a target protein degradation-inducing compound selected from any one of compounds represented by the following general formula (1), their salts, or their solvates. [ka] (where R1 is hydrogen, F, Br, Cl, CH3, OCH 3、 I, CF3 or OCF3, R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. 2. A target protein decomposition inducer compound according to the preceding paragraph 1, having the following composition: The cerebron binder is selected from any one of a compound represented by the following general formula (1), a salt thereof, or a solvate thereof: [ka] (where R1 is hydrogen, F, Br, Cl, CH3, OCH 3、 I, CF3 or OCF3, R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. and the target protein binder is JQ-1 or Birabresib. Targeted protein degradation-inducing compounds. 3. A target protein decomposition-inducing compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (7), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. And the target protein degradation-inducing compound, wherein the target protein binder is Birabresib or JQ-1. 4. A target protein decomposition-inducing compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (8), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. And the target protein degradation-inducing compound, wherein the target protein binder is Birabresib or JQ-1. 5. A target protein decomposition inducer compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (6), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. And the target protein degradation-inducing compound, wherein the target protein binder is Birabresib or JQ-1. 6. A target protein decomposition inducer compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (3), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. And the target protein degradation-inducing compound, wherein the target protein binder is Birabresib or JQ-1. 7. A target protein decomposition-inducing compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (5), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. And the target protein degradation-inducing compound, wherein the target protein binder is Birabresib or JQ-1. 8. A target protein decomposition-inducing compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (4), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. And the target protein degradation-inducing compound, wherein the target protein binder is Birabresib or JQ-1. 9. The target protein degradation-inducing compound according to any one of the preceding items 3 to 8, wherein the protein degradation ability of SALL4 or PLZF is reduced. 10. The target protein degradation-inducing compound according to any one of the preceding items 3 to 8, which has reduced teratogenicity. 11. A composition for cancer treatment comprising any one or more of the target protein degradation-inducing compounds described in any one of items 1 to 10 above. 12. A composition for treating cancer, comprising a compound represented by the following general formula (1), a salt thereof, or a solvate thereof: [ka] (where, R1 is hydrogen, F, Br, Cl, CH3, OCH 3、 I, CF3 or OCF3, R L1 and R L2 are each independently H, a functional group, or an atom. 13. The composition for cancer treatment according to the above item 12, wherein the compound represented by the following general formula (1) is a compound represented by general formula (7), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently H, a functional group, or an atom. 14. The composition for cancer treatment according to the above item 12, wherein the compound represented by the following general formula (1) is a compound represented by general formula (8), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently H, a functional group, or an atom. 15. The composition for cancer treatment according to the preceding item 12, wherein the compound represented by the following general formula (1) is a compound represented by general formula (6), a salt thereof, or a solvate thereof: [ka] (where R L1 and RL2 are each independently H, a functional group, or an atom. 16. The composition for cancer treatment according to the preceding item 12, wherein the compound represented by the following general formula (1) is a compound represented by general formula (3), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently H, a functional group, or an atom. 17. The composition for cancer treatment according to the above item 12, wherein the compound represented by the following general formula (1) is a compound represented by general formula (5), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently H, a functional group, or an atom. 18. A therapeutic agent for chromosome 5-deficient myelodysplastic syndrome, comprising a compound represented by the following general formula (5), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently H, a functional group, or an atom. 19. A therapeutic agent for chromosome 5-deficient myelodysplastic syndrome, comprising a compound represented by the following general formula (3), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently H, a functional group, or an atom.
[0011] Furthermore, the present invention includes the following. 1. A target protein degradation inducer compound having the following composition: "Cerebron binder" - "linker" - "target protein binder", Here, the cerebron binder is a target protein degradation-inducing compound selected from any one of compounds represented by the following general formula (10), their salts, or their solvates. [ka] (wherein X is CH2 or C=O, and R10 is hydrogen, a functional group, an atom, or NR L1 R L2 And R L1 and R L2 is hydrogen, a functional group, or an atom, but any one of them is a functional group or an atom, and R11 is hydrogen, F, Br, Cl, CH3, OCH 3、 I, CF3 or OCF3, and R12 is hydrogen, F, Br, CF3, I, Cl, OH, CH3, OCF3 or OCH3. 2. The target protein decomposition-inducing compound described in the preceding item 1, wherein the target protein binder is JQ-1 or Birabresib. 3. The target protein decomposition inducer compound according to the preceding item 1 or 2, wherein X in the general formula (10) is CH2, R11 is CF3, and R12 is hydrogen. 4. The target protein decomposition inducer compound according to item 1 or 2 above, wherein X in the general formula (10) is CH2, R11 is F, and R12 is hydrogen. 5. The target protein degradation inducer compound according to claim 1 or 2, wherein X in the general formula (10) is CH2, R11 is Cl, and R12 is hydrogen. Effect of the Invention
[0012] The present invention can provide a novel target protein degradation-inducing compound and a cancer therapeutic composition containing said compound, as well as a cancer therapeutic composition with reduced teratogenicity. [Brief description of the drawings]
[0013] [Figure 1] Example of a linker. [Diagram 2] Example of a linker. [Diagram 3] The structures of each thalidomide derivative. [Figure 4] Results of analysis of the affinity (degradation-inducing ability) of each thalidomide derivative for IKZF1, SALL4, and PLZF (left column shows IKZF1, center column shows SALL4, right column shows PLZF). [Diagram 5] Results of degradation analysis of the affinity (degradation-inducing ability) of each thalidomide derivative for IKZF1, SALL4, and CRBN. [Figure 6] Results of an analysis of the affinity (degradation-inducing ability) of thalidomide derivatives with substituents inserted at each meta position for IKZF1, SALL4, and PLZF {(1) shows the structure of each thalidomide derivative with substituents inserted at the meta position used, and (2) shows the affinity analysis results, where the left column shows IKZF1, the center column shows SALL4, and the right column shows PLZF}. [Figure 7] The results of an analysis of the affinity (degradation-inducing ability) of lenalidomide derivatives with substituents inserted at the meta position for IKZF1, SALL4, and PLZF {(1) shows the structure of each thalidomide derivative with substituents inserted at the meta position used, (2) shows the affinity analysis results, X represents IKZF1, Y represents SALI4, and Z represents PLZF}. [Figure 8] Results of analysis of the affinity of F3C-lenalidomide and F3CO-lenalidomide to SALL4 and PLZF {(1) shows the structures of F3C-lenalidomide and F3CO-lenalidomide, (2) shows the results of affinity analysis, where the left column shows IKZF1, the center column shows SALL4, and the right column shows PLZF}. [Figure 9] (1) Overview of the method for measuring the binding ability to CRBN. (2) Results of the binding ability to CRBN of lenalidomide derivatives with substituents at each meta position. [Figure 10] Results of cell culture intrinsic proteolysis of lenalidomide derivatives with substituents inserted at each meta position. [Figure 11] Anticancer activity of lenalidomide derivatives with substituents inserted at each meta position against cultured cells derived from multiple myeloma. [Figure 12] Results of anticancer activity of lenalidomide derivatives with substituents inserted at each meta position against cultured cells derived from chromosome 5 deletion myelodysplastic syndrome. [Figure 13]Confirmation of the neoproteolytic activity of known PROTACs dBET1 and ARV-825 (1) and the anticancer activity against cultured cells derived from multiple myeloma (2). [Figure 14] Schematic diagram of the action of the PROTAC of the present invention. [Figure 15] Diagram of the structure of each PROTAC. [Figure 16] Confirmation of the selectivity of the PROTAC of the present invention for the neo-substrate of cerebron binder (1) and the anticancer activity against cultured cells derived from multiple myeloma (2). [Figure 17] Results of the ability of the PROTAC of the present invention to induce degradation of SALL4 and PLZF. [Figure 18] Confirmation of the anticancer effect of the PROTAC of the present invention. [Figure 19] Disassembly evaluation of CC-220's SALL4. [Figure 20] Examples of known PROTACs. [Figure 21] Examples of known PROTACs. [Figure 22] Examples of known PROTACs. [Figure 23] Examples of known PROTACs. [Figure 24] Examples of known PROTACs. [Diagram 25] Examples of known PROTACs. [Figure 26] Examples of known PROTACs. [Figure 27] Examples of known PROTACs. [Figure 28] Examples of known PROTACs. [Figure 29] Examples of known PROTACs. [Diagram 30] Examples of known PROTACs. [Diagram 31] Examples of known PROTACs. [Diagram 32] Examples of known PROTACs. [Diagram 33] Evaluation of the antitumor effect of PROTAC in a mouse xenograft model using IMR32 cells (neuroblastoma cells). [Diagram 34] Results of the degradation induction ability of thalidomide, pomalidomide, and lenalidomide. [Diagram 35] Results of degradation induction ability of thalidomide derivatives modified at the 4-position. [Diagram 36] Results of the degradation induction ability of substitutions at positions 5, 6, etc. of the pomalidomide skeleton. [Figure 37] Results of the degradation induction ability of substitutions at positions 6, 7, etc. of the lenalimid skeleton. [Figure 38] Results of degradation induction ability of 7-position modified pomalidomide-linker-JQ-1 derivative (PROTAC). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] (Subject of the present invention) The subject of the present invention is as follows: A composition for cancer treatment comprising a compound represented by the following general formula (1) or general formula (10), a salt thereof, or a solvate thereof (hereinafter, sometimes referred to as the "composition for cancer treatment of the present invention"). A targeted protein decomposition-inducing compound (PROTAC compound, hereinafter sometimes referred to as "the targeted protein decomposition-inducing compound of the present invention" or "the PROTAC compound of the present invention") having the following configuration. "Cerebron binder" - "Linker" - "Target protein binder"
[0015] [ka]
[0016] R1 is hydrogen, F, Br, Cl, CH3, OCH 3、 I, CF3 or OCF3, R L1 and R L2 is a hydrogen, a functional group, or an atom, provided that one of them is a functional group or an atom.
[0017] [ka]
[0018] X is CH2 or C=O, and R10 is hydrogen, a functional group, an atom, or NR L1 R L2 And R L1 and R L2 is hydrogen, a functional group, or an atom, but any one of them is a functional group or an atom, and R11 is hydrogen, F, Br, Cl, CH3, OCH 3、 and R12 is hydrogen, F, Br, CF3, I, Cl, OH, CH3, OCF3, or OCH3.
[0019] In the case of the target protein degradation inducer compound of the present invention, R L1 and R L2 Either one or both of are bonded to the linker or are part of the linker. The functional group is not particularly limited as long as it is capable of binding (particularly, covalently) or coupling with the linker described below, and examples thereof include alcohols, ketones, carboxylic acids, amines, ethers, and the like. The atom is not particularly limited as long as it can be bonded or coupled to the linker described below, and examples thereof include oxygen, nitrogen, sulfur, phosphorus, halogens, heterocyclic amines (piperazine, piperidine), and the like.
[0020] (Cancer Treatment Composition of the Present Invention) The composition for cancer treatment of the present invention contains a compound represented by the above general formula (1) or general formula (10), a salt thereof, or a solvate thereof as an active ingredient. Examples of the compound represented by the above general formula (1) or general formula (10) include the following. In addition, the active ingredient can function as a cerebron binder. There is no particular limitation on the salt as long as it is pharmacologically acceptable, but specifically, acid addition salts, base addition salts, and the like are preferred. The solvate is not particularly limited as long as it is pharmacologically acceptable, but specifically, hydrates, ethanol solvates, etc. are preferred.
[0021] (F-lenalidomide or its derivatives) An example of general formula (1) is the following general formula (3).
[0022] [ka]
[0023] R L1 and R L2 are each independently H, a functional group, or an atom. F-lenalidomide is a lenalidomide derivative in which fluorine is bonded to position 6 of the aminoisoindolinone ring of lenalidomide. F-lenalidomide can be synthesized, for example, by appropriately modifying the raw material compounds, reaction steps, etc., in a known method for synthesizing lenalidomide so that fluorine is present at position 6 of the aminoisoindolinone ring. F-lenalidomide exists as S- and R-optical isomers, and the present invention is directed to the S- or R-isomer, or a mixture thereof (such as a racemic mixture).
[0024] (Lenalidomide or its derivatives) An example of general formula (1) is the following general formula (4).
[0025] [ka]
[0026] R L1 and R L2 are each independently H, a functional group, or an atom. Lenalidomide is commercially available, and can be produced by a method known per se. Lenalidomide exists as S- and R-optical isomers, and the present invention is directed to the S- or R-isomer, or a mixture thereof (such as a racemic mixture).
[0027] (Cl-lenalidomide or its derivatives) An example of general formula (1) is the following general formula (5).
[0028] [ka]
[0029] R L1 and R L2 are each independently H, a functional group, or an atom. Cl-lenalidomide is a lenalidomide derivative in which chlorine is bonded to position 6 of the aminoisoindolinone ring of lenalidomide. Cl-lenalidomide can be synthesized, for example, by appropriately modifying the raw material compounds, reaction steps, etc., in a known method for synthesizing lenalidomide so that chlorine is present at position 6 of the aminoisoindolinone ring. Cl-lenalidomide exists as S- and R-optical isomers, and the present invention is directed to the S- or R-isomer, or a mixture thereof (such as a racemic mixture).
[0030] (Br-lenalidomide or its derivatives) An example of general formula (1) is the following general formula (6).
[0031] [ka]
[0032] R L1 and R L2 are each independently H, a functional group, or an atom. Br-lenalidomide is a lenalidomide derivative in which Br is bonded to position 6 of the aminoisoindolinone ring of lenalidomide. Br-lenalidomide can be synthesized, for example, by appropriately changing the raw material compounds, reaction steps, etc., in a known synthesis method of lenalidomide so that Br is present at position 6 of the aminoisoindolinone ring. Br-lenalidomide exists as S- and R-optical isomers, and the present invention is directed to the S- or R-isomer, or a mixture thereof (such as a racemic mixture).
[0033] (F3C-lenalidomide or its derivatives) An example of general formula (1) is the following general formula (7).
[0034] [ka]
[0035] R L1 and R L2 are each independently H, a functional group, or an atom. F3C-lenalidomide is a lenalidomide derivative in which CF3 is bound to position 6 of the aminoisoindolinone ring of lenalidomide. F3C-lenalidomide can be synthesized, for example, by appropriately modifying the raw material compounds, reaction steps, etc., in a known synthesis method of lenalidomide so that CF3 is present at position 6 of the aminoisoindolinone ring. F3C-lenalidomide exists as S- and R-optical isomers, and the present invention is directed to the S- or R-isomer, or a mixture thereof (such as a racemic mixture).
[0036] (F3CO-lenalidomide or its derivatives) An example of general formula (1) is the following general formula (8).
[0037] [ka]
[0038] R L1 and R L2 are each independently H, a functional group, or an atom. F3CO-lenalidomide is a lenalidomide derivative in which F3CO is bound to position 6 of the aminoisoindolinone ring of lenalidomide. F3CO-lenalidomide can be synthesized, for example, by appropriately modifying the raw material compounds, reaction steps, etc., in a known synthesis method of lenalidomide so that F3CO is present at position 6 of the aminoisoindolinone ring. F3CO-lenalidomide exists as S- and R-optical isomers, and the present invention is directed to the S- or R-isomer, or a mixture thereof (such as a racemic mixture).
[0039] In addition to the above compounds, the present invention also covers the thalidomide derivatives, pomalidomide derivatives, and lenalidomide derivatives shown in Figures 35 to 38.
[0040] (Target protein degradation-inducing compound of the present invention) The target protein decomposition inducer compound of the present invention comprises a structure of "cerebron binder"-"linker"-"target protein binder". The target protein decomposition inducer compound also includes its salt or solvate forms. There is no particular limitation on the salt as long as it is pharmacologically acceptable, but specifically, acid addition salts, base addition salts, etc. are preferred. There is no particular limitation on the solvate as long as it is pharmacologically acceptable, but specifically, hydrates, ethanol solvates, etc. are preferred. Here, the cerebron binder refers to one or more compounds selected from the above-mentioned compounds represented by general formula (1) or general formula (10), compounds represented by general formula (3), compounds represented by general formula (4), compounds represented by general formula (5), compounds represented by general formula (6), compounds represented by general formula (7), and compounds represented by general formula (8).
[0041] (Linker) The linker of the present invention can be any known linker as long as both ends of the linker can be linked (particularly, chemically (covalently) linked or coupled) to the cerebron binder and the target protein binder. The linker can be linked to the cerebron binder and the target protein binder by a known method. For example, the literature "Frontiers in Chemistry, 9, 707317 (2021)" can be referred to as a method for linking a linker in a known PROTAC. Further, for example, the linker can be represented by the formula:
[0042] [ka]
[0043] wherein q is an integer greater than 1; and L is independently a bond, CR M1 R M2 , O, S, SO, SO2, NR M3 , SO2NR M3 ,SONR M3 ,CONR M3 , N.R. M3 CONR M4 , N.R. M3 SO2NR M4 , CO, CR M1 =CR M2 , C≡C, SiR M1 R M2 , P(O)R M1 , P(O)OR M1 , N.R. M3 C(=NCN)NR M4 , N.R. M3 C(=NCN), NR M3 C(=CNO2)NR M4 , 0 to 6 R M1 and / or R M2 C optionally substituted with a group 3-11 Cycloalkyl, 0 to 6 R M1 and / or R M2 C optionally substituted with a group 3-11 Heterocyclyl, 0 to 6 R M1 and / or R M2 aryl optionally substituted with a group, 0 to 6 R M1 and / or R M2 The aryl group may be selected from the group consisting of heteroaryl, which may be optionally substituted with a group. R M1 , R M2 , R M3 , R M4 , and R M5 are independently H, halo, and C 1-8 Alkyl, OC 1-8 Alkyl, SC 1-8 Alkyl, NHC 1-8 Alkyl, N(C 1-8 Alkyl)2, C3-11 Cycloalkyl, aryl, heteroaryl, C 3-11 Heterocyclyl, OC 1-8 Cycloalkyl, SC 1-8 Cycloalkyl, NHC 1-8 Cycloalkyl, N(C 1-8 Cycloalkyl)2, N(C 1-8 Cycloalkyl)(C 1-8 Alkyl), OH, NH2, SH, SO2C 1-8 Alkyl, P(O)(OC 1-8 Alkyl)(C 1-8 alkyl), P(O)(OC 1-8 Alkyl)2, CC-C 1-8 Alkyl, CCH, CH=CH(C 1-8 alkyl), C(C 1-8 Alkyl)=CH(C 1-8 alkyl), C(C 1-8 Alkyl)=C(C 1-8 alkyl)2, Si(OH)3, Si(C 1-8 alkyl)3, Si(OH)(C 1-8 Alkyl)2, COC 1-8 Alkyl, CO2H, halogen, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NHC 1-8 Alkyl, SO2N(C 1-8 Alkyl)2, SONHC 1-8 Alkyl, SON(C 1-8 Alkyl)2, CONHC 1-8 Alkyl, CON(C 1-8 Alkyl)2, N(C 1-8 alkyl)CONH(C 1-8 alkyl), N(C 1-8 Alkyl)CON(C 1-8 alkyl)2, NHCONH(C 1-8 alkyl), NHCON(C 1-8 alkyl)2, NHCONH2, N(C 1-8 Alkyl)SO2NH(C 1-8 alkyl), N(C 1-8 Alkyl)SO2N(C 1-8 alkyl)2, NHSO2NH(C 1-8 alkyl), NHSO2N(C 1-8The alkyl group may be selected from the group consisting of NHSO2NH2, NHSO2NH2, and NHSO2NH2. Also, if q is greater than 1, R M1 or R M2 each independently linking to another L group, M5 It is possible to form cycloalkyl and / or heterocyclyl moieties which can be further substituted with groups. Specifically, examples of linkers include those shown in FIGS.
[0044] (Target protein degradation-inducing compound of the present invention) As shown in the following Examples, the target protein decomposition-inducing compound of the present invention has reduced ability to induce degradation of SALL4, PLZF, etc., and can therefore be applied to a variety of diseases (particularly cancer types). If the target protein decomposition inducer compound of the present invention has the cerebron binder of the present invention, it can be used as an active ingredient in therapeutic agents for various diseases by including the known target protein binders shown in Figures 20 to 32. For example, based on the structure of ARV-825 No. 1 in Figure 20, if the target protein degradation-inducing compound of the present invention is structured as "cerebron binder of the present invention"-"linker"-"JQ1 or OTX-015 (target protein binder)", the compound can be used as an active ingredient in a therapeutic agent for multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), neuroblastoma, T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia (AML) or Burkitt's lymphoma. For example, based on the structure of SIAIS178 No. 5 shown in Figure 21, if the structure of the target protein degradation-inducing compound of the present invention is "cerebron binder of the present invention"-"linker"-"dasatinib (target protein binder)", the compound can be used as an active ingredient in a treatment for CML (chronic myeloid leukemia). For example, if the structure of the target protein degradation-inducing compound of the present invention is based on the structure of UNC6852 No. 15 shown in Figure 25 and the structure is "cerebron binder of the present invention"-"linker"-"EED226 (target protein binder)", the compound can be used as an active ingredient in a therapeutic agent for diffuse large B-cell lymphoma (DLBCL). For example, if the structure of the target protein decomposition-inducing compound of the present invention is based on the structure of DGY-08-097 No. 40 shown in Figure 31 and the structure is "cerebron binder of the present invention"-"linker"-"telaprevir (target protein binder)", the compound can be used as an active ingredient in a viral treatment agent. For example, based on the structure of GSK983 No. 41 in Figure 31, if the structure of the target protein degradation-inducing compound of the present invention is "cerebron binder of the present invention"-"linker"-"GSK4027 (target protein binder)", the compound can be used as an active ingredient of an anti-inflammatory agent. For example, based on the structure of QC-01-175 No. 42 in Figure 32, if the structure of the target protein decomposition-inducing compound of the present invention is "cerebron binder of the present invention"-"linker"-"AV-1451 (target protein binder)", the compound can be used as an active ingredient for treating Alzheimer's disease and frontotemporal dementia. Based on the above examples, those skilled in the art can design target protein decomposition-inducing compounds of the present invention, including the cerebron binders of the present invention, by referring to the structures of known target protein decomposition-inducing compounds shown in Figures 20 to 32.
[0045] (Target protein binder) The "target protein binder" of the present invention can be a target protein binder used in known PROTACs, and examples thereof include the following. JQ-1(CAS No.:1268524-70-4) OTX015 (CAS No.:202590-98-5) Darolutamide (CASNo. :1297538-32-9) Ceritinib (CAS No. :1032900-25-6) Brigatinib(CAS No.:1197953-54-0) Crizotinib (CAS No.:877399-52-5) Alectinib(CAS No.:1256580-46-7) Venetoclax (CAS No. :1257044-40-8) Dasatinib (CAS No. :302962-49-8) Bosutinib (CAS No. :380843-75-4) RX-37(CAS No.:1627715-60-9) BI-882370 (CAS No. :1392429-79-6) ibrutinib (CAS No.:936563-96-1) CGI1746(CAS No.:910232-84-7) Palbociclib (CAS No.:571190-30-2) Ribociclib (CAS No.: 1211441-98-3) Abemaciclib(CAS No.:1231929-97-7) Apcin-A (CAS No. :1683617-62-0) Apcin(CAS No. :300815-04-7) UNC1999(CAS No.:1431612-23-5) EED226(CAS No.:2083627-02-3) Dacomitinib (CASNo. :1110813-31-4) Lapatinib (CAS No. :388082-78-8) Gefitinib (CAS No.:184475-35-2) afatinib (CAS No.:850140-72-6) Quizartinib (AC220) (CAS No.:950769-58-1) Gilteritinib(CASNo.:1254053-43-4.) MLN-518 (CAS No. :387867-13-2) Sunitinib (CAS No.:341031-54-7) Ponatinib (CAS No.:943319-70-8) ZYF0033 MI-1061 (CAS No. :1410737-34-6) MI-77301 (CAS No. :1303607-60-4) PD0325901(CAS No.:391210-10-9) EPZ015666(CAS No.:1616391-65-1) RA190 (CAS No. :1617495-03-0) SI-109 (CAS No. :2429877-30-3) CJ-887 (CAS No. :1220952-08-8) GNF-8625(CAS No.:1196546-33-4) I-BRD9 (CAS No. :1714146-59-4) BI-7273(CAS No.:1883429-21-7) cortistatin A (CAS No.: 882976-95-6) SNS-032 (CAS No. :345627-80-7) wogonin (CAS No. :632-85-9) CX-4945 (CAS No. :1009820-21-6) Defactinib(CAS No.:1073154-85-4) quizartinib(CAS No.: 950769-58-1) nexturastat A(CAS No.:1403783-31-2) EED226(CAS No.:2083627-02-3) UNC1999(CAS No. :1431612-23-5) Telaprevir (CAS No.:402957-28-2) GSK4027(CAS No. :2079896-25-4) AV-1451 (T807) (CASNo. :1415379-56-4)
[0046] (Target disease) Examples of target diseases include, but are not limited to, the following. Multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), neuroblastoma, T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid leukemia (AML), Burkitt's lymphoma, castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC), T-cell lymphoma (TCL), chronic myeloid leukemia (CML), triple-negative breast cancer (TNBC), melanoma, mantle cell lymphoma (MCL), colorectal cancer (CRC), triple-negative breast cancer (TNBC), ovarian cancer, multiple myeloma (MM), acute T-cell lymphoma lymphoma), breast cancer, ER (estrogen receptor) positive breast cancer cells (ER+BC), liver cancer, prostate cancer, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), viral diseases, inflammatory diseases, and Alzheimer's and frontotemporal dementia.
[0047] (Examples of target protein degradation-inducing compounds of the present invention) Preferred examples of the target protein degradation-inducing compound of the present invention are shown below, but are not particularly limited. "Cerebron binder" - "Linker" - "Target protein binder" "Lenalidomide" - "Linker" - "JQ-1 or Birabresib" "F-lenalidomide" - "Linker" - "JQ-1 or Birabresib" "F3C-lenalidomide" - "Linker" - "JQ-1 or Birabresib" "F3CO-lenalidomide" - "Linker" - "JQ-1 or Birabresib" "Cl-lenalidomide" - "Linker" - "JQ-1 or Birabresib" "Br-lenalidomide" - "Linker" - "JQ-1 or Birabresib" "F-pomalidomide" - "Linker" - "JQ-1 or Birabresib" "F3C-pomalidomide" - "Linker" - "JQ-1 or Birabresib"
[0048] (Synthesis Example of the Target Protein Degradation Inducing Compound of the Present Invention) The synthesis of the target protein decomposition-inducing compound of the present invention can be carried out by appropriately modifying a publicly known method for synthesizing a target protein decomposition-inducing compound. For example, "F-lenalidomide"-"linker"-"JQ-1 or Birabresib" can be synthesized by using "F-lenalidomide" instead of "lenalidomide" in the synthesis process of ARV-825 (CAS No.: 1818885-28-7), a known target protein degradation inducer compound.
[0049] (Cancer Tumors Applicable to the Cancer Therapeutic Composition of the Present Invention) The preferred cancers to which the following compounds contained as active ingredients are applicable are blood cancers (multiple myeloma, myelodysplastic syndrome, acute myeloid leukemia, etc.) based on the results of the following examples. Compounds represented by general formula (4) (lenalidomide) Compounds represented by general formula (5) (Cl-lenalidomide) Compounds represented by general formula (3) (F-lenalidomide) Lenalidomide - Linker - JQ-1 or Birabresib
[0050] (Cancer Tumors Applicable to the Cancer Therapeutic Composition of the Present Invention) The preferred cancers for which the following compounds contained as active ingredients are used are those in which teratogenicity has been reduced according to the results of the following examples, and include not only blood cancers but also the following cancer types. Compounds represented by general formula (5) (Cl-lenalidomide) Compounds represented by general formula (3) (F-lenalidomide) Compounds represented by general formula (6) (Br-lenalidomide) Compounds represented by general formula (7) (F3C-lenalidomide) Compounds represented by general formula (8) (F3CO-lenalidomide) 〇 "F-lenalidomide" - "Linker" - "JQ-1 or Birabresib" 〇 "F3C-lenalidomide" - "Linker" - "JQ-1 or Birabresib" 〇 "F3CO-lenalidomide" - "Linker" - "JQ-1 or Birabresib" 〇 "Br-lenalidomide" - "Linker" - "JQ-1 or Birabresib" 〇 "Cl-lenalidomide" - "Linker" - "JQ-1 or Birabresib" carcinoma Bladder cancer, intestinal cancer, breast cancer, cervical cancer, colon cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, leukemia, malignant lymphoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, malignant melanoma, myeloproliferative disorders, multiple myeloma, sarcoma, breast cancer, uterine cancer, lung cancer, testicular cancer, thyroid cancer, esophageal cancer, etc.
[0051] (Reduction of teratogenicity) Teratogenicity refers to the property or action of certain substances, such as drugs, to inhibit the normal development of living organisms and cause birth defects, and is used synonymously with teratogenicity. The term "reduced teratogenicity" in the present invention can be expressed by assuming that the protein degradation ability of SALL4, PLZF, CK1α, IKZF1 or IKZF3 due to direct or indirect binding of lenalidomide or lenalidomide, which is an E3 ligase (cereblon) binder in a PROTAC compound, to cereblon, is 100 (see Example 17). The resolution of SALL4 by F-Len, as compared with lenalidomide, is in the range of 1 to 70, preferably 5 to 60, and more preferably 10 to 50. The resolution of PLZF by F-Len, as compared with lenalidomide, is in the range of 0 to 30, preferably 0 to 20, and more preferably 0 to 10. The resolution of SALL4 of Cl-Len is in the range of 0.5 to 20, preferably 1.0 to 15, more preferably 1.5 to 10, compared with lenalidomide. The resolution of PLZF of Cl-Len is in the range of 0 to 30, preferably 0 to 20, more preferably 0 to 10, compared with lenalidomide. The resolution of IKZF1 of Cl-Len is in the range of 50 to 90, preferably 60 to 85, more preferably 65 to 80, compared with lenalidomide. The resolution of IKZF3 of Cl-Len is in the range of 30 to 70, preferably 35 to 65, more preferably 40 to 60, compared with lenalidomide. The resolution of SALL4 of Br-Len is in the range of 0.5 to 40, preferably 1.0 to 35, more preferably 1.5 to 30, compared with lenalidomide. The resolution of PLZF of Br-Len is in the range of 0 to 30, preferably 0 to 20, more preferably 0 to 10, compared with lenalidomide. The resolution of IKZF1 of Br-Len is in the range of 15 to 50, preferably 20 to 45, more preferably 25 to 40, compared with lenalidomide. The resolution of IKZF3 of Br-Len is in the range of 0 to 30, preferably 0 to 20, more preferably 0 to 10, compared with lenalidomide. The resolution of SALL4 by F3C-Len is in the range of 0 to 30, preferably 0 to 20, more preferably 0 to 10, compared with lenalidomide. The resolution of CK1α by F3C-Len is in the range of 0 to 90, compared with lenalidomide. The resolution of IKZF1 by F3C-Len is in the range of 0 to 30, preferably 0 to 20, more preferably 0 to 10, compared with lenalidomide. The resolution of IKZF3 by F3C-Len is in the range of 0 to 30, preferably 0 to 20, more preferably 0 to 10, compared with lenalidomide. The resolution of SALL4 of F-Len-PROTAC is in the range of 30 to 90, preferably 40 to 80, more preferably 50 to 70, compared to Len-PROTAC. The resolution of PLZF of F-Len-PROTAC is in the range of 0 to 60, preferably 5 to 50, compared to Len-PROTAC. The resolution of IKZF3 of F-Len-PROTAC is in the range of 60 to 90, compared to Len-PROTAC. The resolution of SALL4 of Cl-Len-PROTAC is in the range of 5 to 50, preferably 10 to 40, more preferably 15 to 30, compared to Len-PROTAC. The resolution of PLZF of Cl-Len-PROTAC is in the range of 0 to 70, preferably 0 to 60, compared to Len-PROTAC. The resolution of IKZF1 of Cl-Len-PROTAC is in the range of 70 to 95, compared to Len-PROTAC. The resolution of IKZF3 of Cl-Len-PROTAC is in the range of 20 to 80, preferably 30 to 70, more preferably 40 to 60, compared to Len-PROTAC. The resolution of SALL4 of F3C-Len-PROTAC is in the range of 0 to 30, preferably 0 to 20, more preferably 0 to 10, compared to Len-PROTAC. The resolution of PLZF of F3C-Len-PROTAC is in the range of 0 to 30, preferably 0 to 15, compared to Len-PROTAC. The resolution of CK1α of F3C-Len-PROTAC is in the range of 0 to 30, preferably 0 to 20, more preferably 0 to 10, compared to Len-PROTAC. The resolution of IKZF1 of F3C-Len-PROTAC is in the range of 5 to 50, preferably 10 to 40, more preferably 15 to 35, compared to Len-PROTAC. The resolution of IKZF3 of F3C-Len-PROTAC is in the range of 10 to 70, preferably 20 to 60, more preferably 30 to 50, compared to Len-PROTAC. The inventors have confirmed that thalidomide derivatives with reduced protein degradation ability of SALL4 or PLZF have reduced teratogenicity (see EMBO J (2021) 40: e105375).
[0052] (Method of administering the cancer therapeutic composition of the present invention) The cancer therapeutic composition of the present invention can be administered orally or parenterally. For oral administration, known dosage forms such as tablets, capsules, coated tablets, troches, and liquids such as solutions or suspensions can be used. For parenteral administration, intravenous, intramuscular, or subcutaneous administration by injection, transmucosal administration such as nasal or oral administration using sprays or aerosols, rectal administration using suppositories, and transdermal administration using patches, liniments, gels, and the like can be mentioned. Preferably, oral administration, nasal administration, or intravenous administration by injection can be mentioned.
[0053] (Carrier contained in the cancer therapeutic composition of the present invention) In addition to the medicinal ingredient, the composition for cancer treatment of the present invention may contain an appropriate pharma- ceutically acceptable carrier well known to those skilled in the art, as appropriate, depending on the administration form, etc. Examples of pharma- ceutically acceptable carriers include antioxidants, stabilizers, preservatives, flavoring agents, colorants, dissolving agents, solubilizing agents, surfactants, emulsifiers, antifoaming agents, viscosity modifiers, gelling agents, absorption enhancers, dispersants, excipients, and pH adjusters.
[0054] (Method of formulating the composition for treating cancer of the present invention) When the cancer therapeutic composition of the present invention is prepared as an injectable formulation, it is preferably in the form of a solution or suspension, and when it is intended for transmucosal administration such as nasal or oral cavity, it is preferably in the form of a powder, drops, or aerosol. When it is intended for rectal administration, it is preferably in the form of a semisolid formulation such as a cream or suppository. All of these formulations can be prepared by any method known to those skilled in the pharmaceutical art, for example, as described in Remington's Pharmaceutical Sciences (Mack Publishing Company, Easton, PA, 1970). The injectable formulation can contain carriers such as plasma-derived proteins such as albumin, amino acids such as glycine, and sugars such as mannitol, and can also contain buffers, solubilizers, and isotonic agents. When it is used as an aqueous formulation or a lyophilized formulation, it is preferable to add a surfactant such as Tween (registered trademark) 80 or Tween (registered trademark) 20 to prevent aggregation. Furthermore, parenteral dosage forms other than injection preparations may contain distilled water or physiological saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, and hydrogenated naphthalene. For example, preparations for rectal administration such as suppositories contain, as common excipients, for example, polyalkylene glycols, petrolatum, and cacao oil. Vaginal preparations may contain absorption enhancers such as bile salts, ethylenediamine salts, and citrate salts. Preparations for inhalation may be solid and may contain, for example, lactose as an excipient, and nasal drops may be water or oil solutions.
[0055] (Method of administering the cancer therapeutic composition of the present invention) The exact dosage and administration schedule of the cancer therapeutic composition of the present invention can be adjusted depending on the required amount, treatment method, degree of disease or need, etc. for each individual subject to be treated. The dosage can be specifically determined according to the age, body weight, general health condition, sex, diet, administration time, administration method, excretion rate, drug combination, and the patient's condition, and may be determined taking other factors into consideration. The daily dosage of the cancer therapeutic composition of the present invention varies depending on the patient's condition and body weight, type of compound, administration route, etc., but for example, it is desirable to administer the active ingredient amount of about 0.01 to 1000 mg / person / day, preferably 0.1 to 500 mg / person / day, in the case of parenteral administration, and about 0.01 to 500 mg / person / day, preferably 0.1 to 100 mg / person / day, in the case of oral administration.
[0056] The present invention will be described in more detail below with reference to examples. However, the following examples should be regarded as an aid for gaining a concrete understanding of the present invention, and the scope of the present invention is not limited by the following examples in any way. EXAMPLES
[0057] (Confirmation of the ability of each thalidomide derivative to interact with IKZF1, SALL4, and PLZF) In this example, the affinity (degradation-inducing ability) of each thalidomide derivative for IKZF1, SALL4, and PLZF was confirmed by biochemical interaction analysis.
[0058] (Experimental Method) FLAG-GST-IKZF1, -SALL4, -PLZF and N-terminally biotinylated bls-CRBN were synthesized as recombinant proteins using a wheat cell-free protein synthesis system. A 10-μl mixture containing 0.5 μl of the synthesized bls-CRBN was prepared in AlphaScreen buffer (100 mM Tris (pH 8.0), 0.01% Tween20, 100 mM NaCl, and 1 mg / mL BSA). A 5-μl mixture containing 0.8 μl of FLAG-GST-protein was prepared in AlphaScreen buffer. A 5-μl mixture containing DMSO (final concentration 0.5%) or thalidomide derivatives at the final concentrations shown in Figure 4 was prepared in AlphaScreen buffer. The three mixtures were then mixed in a 384-well AlphaPlate (PerkinElmer) and left to stand at 26°C for 1 h. Next, 5 μl of detection mixture containing 0.2 μg / ml of anti-DYKDDDDK antibody (FUJIFILM WakoPure Chemical), 0.08 μl of streptavidin donor beads (PerkinElmer), and 0.08 μl of protein A acceptor beads (PerkinElmer) was prepared in AlphaScreen buffer. 5 μl of detection mixture was added to each well, and the plate was incubated at 26°C for 1 hour, after which the luminescence signal was detected using an Envision plate reader (PerkinElmer).
[0059] (result) The structures of the thalidomide derivatives used in this example are shown in Figure 3. As is clear from the results in Figure 4, it was confirmed that the insertion of a substituent at the meta position of lenalidomide reduces the affinity (degradation-inducing ability) for SALL4 and PLZF, which are teratogenic proteins. EXAMPLES
[0060] (Confirmation of the ability of each thalidomide derivative to induce degradation of IKZF1 and SALL4) In this example, the affinity (degradation-inducing ability) of each thalidomide derivative for IKZF1 and SALL4 was confirmed by analyzing the degradation of overexpressed neo-substrates (SALL4 and IKZF1) in cultured cells.
[0061] (Experimental Method) HEK293T cultured cells were seeded in a 48-well cell culture plate (BD Falcon) and cultured overnight at 37°C and 5% CO2. Then, AGIA-SALL4 and Myc-IKZF1 were transfected using polyethyleneimine (PEI)Max (MW 40,000) (PolyScience, Inc.). 6 hours after transfection, DMSO (final concentration 0.1%) or thalidomide derivatives at the final concentrations shown in Figure 5 were administered. 18 hours after drug administration, the medium supernatant was removed with an aspirator, and the cultured cells were collected and dissolved using 1×SDS sample buffer (62.5mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol). The collected cell extract was boiled at 95°C for 5 minutes and electrophoresed using polyacrylamide gel. Next, immunoblot was performed to detect each protein using the antibodies shown in Figure 5.
[0062] (result) As is clear from the results in Figure 5, insertion of a substituent at the meta position of lenalidomide reduces the ability to induce degradation of SALL4, a teratogenic protein, as in Example 1, but maintains the ability to induce degradation of IKZF1, and it was confirmed that the affinity for CRBN is not reduced. EXAMPLES
[0063] (Confirmation of the ability of thalidomide derivatives with substituents inserted at each meta position to induce interactions with IKZF1, SALL4, and PLZF) In this example, the affinity (degradation-inducing ability) of thalidomide derivatives with substituents inserted at each meta position for IKZF1, SALL4, and PLZF was confirmed by biochemical interaction analysis.
[0064] (Experimental Method) FLAG-GST-IKZF1, -SALL4, -PLZF, and N-terminally biotinylated bls-CRBN were synthesized as recombinant proteins using a wheat cell-free protein synthesis system. A 10-μl mixture containing 0.5 μl of the synthesized bls-CRBN was prepared in AlphaScreen buffer (100 mM Tris (pH 8.0), 0.01% Tween20, 100 mM NaCl, and 1 mg / mL BSA). A 5-μl mixture containing 0.8 μl of FLAG-GST-protein was prepared in AlphaScreen buffer. A 5-μl mixture containing DMSO (final concentration 0.5%) or thalidomide derivatives at the final concentrations shown in Figure 6 was prepared in AlphaScreen buffer. The three mixtures were then mixed in a 384-well AlphaPlate (PerkinElmer) and left to stand at 26°C for 1 h. Next, 5 μl of detection mixture containing 0.2 μg / ml of anti-DYKDDDDK antibody (FUJIFILM WakoPure Chemical), 0.08 μl of streptavidin donor beads (PerkinElmer), and 0.08 μl of protein A acceptor beads (PerkinElmer) was prepared in AlphaScreen buffer. 5 μl of detection mixture was added to each well, and the plate was incubated at 26°C for 1 hour, after which the luminescence signal was detected using an Envision plate reader (PerkinElmer).
[0065] (result) As is clear from the results in Figure 6, compared with the insertion of a substituent at the meta position of thalidomide and the insertion of a substituent at the meta position of pomalidomide, the insertion of a substituent at the meta position of lenalidomide reduced the affinity for the teratogenic proteins SALL4 and PLZF, while maintaining the affinity for IKZF1, a drug target protein for blood cancer. For this reason, lenalidomide and lenalidomide derivatives with substituents inserted at each meta position were used in the following Examples. Note that, although it is necessary to maintain affinity for IKZF for blood cancer, affinity for IKZF is generally not necessary. EXAMPLES
[0066] (Synthesis of Lenalidomide Derivatives with Substituents Inserted at the Meta Position) In this example, lenalidomide derivatives with substitution at each meta position were synthesized. Details are as follows. Lenalidomide was purchased from FUJIFILM WakoPure Chemical. 5-hydroxythalidomide (5HT) was synthesized by the method disclosed in Bioorg. Med Chem Lett 19:3973-3976.
[0067] (Synthesis of F-lenalidomide) It was synthesized by the following procedure.
[0068] [ka]
[0069] 438 mg (1.50 mmol) of methyl 2-(bromomethyl)-5-fluoro-3-nitrobenzoate (reference: WO2005034939 A1) and 247 mg (1.50 mmol) of 3-aminopiperidine-2,6-dione hydrochloride were dissolved in 1.5 mL of N,N-dimethylformamide, and then 0.25 mL (1.8 mmol) of triethylamine was added and stirred at 50° C. for 12 hours. After cooling to room temperature, water was added and the mixture was extracted with ethyl acetate. After drying with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure. The obtained solid was purified by silica gel column chromatography to obtain 150 mg of 3-(6-fluoro-4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione in a yield of 33%. The compound data for 3-(6-fluoro-4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione (see WO 2016065980 A1, WO 2019079701 A1) is shown below. 1H NMR (300 MHz, DMSO- d6) δ (ppm) 11.05 (s, 1H), 8.38 (dd, J = 9.1, 1.9 Hz, 1H),8.11 (dd, J = 6.8, 1.7 Hz, 1H), 5.22 - 5.11 (m, 1H), 4.80 (dd, J = 35.2, 18.9Hz, 2H), 2.99 - 2.78 (m, 1H), 2.64 - 2.50 (m, 2H), 2.07 - 1.90 (m, 1H). 19F NMR (282 MHz, DMSO- d6) δ (ppm) 109.38 (dd, J = 7.7 Hz, 1F). ESIMS calculated for C13H9FN3O5 ([MH]-) 306.05, found 306.05
[0070] [ka]
[0071] 100 mg (0.327 mmol) of 3-(6-fluoro-4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione was dissolved in 4.1 mL of 1,4-dioxane, and the reaction solution was degassed. Next, 22.9 mg of palladium hydroxide carbon was added, and the inside of the reaction vessel was replaced with hydrogen. After stirring for 3 hours, the reaction solution was filtered, and the solvent was distilled off under reduced pressure to obtain 16.1 mg of 3-(4-amino-6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione in 18% yield. The compound data for 3-(4-amino-6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione are shown below. 1 H NMR(300 MHz, DMSO- d6) δ (ppm) 11.03 (s, 1H), 6.69 - 6.49 (m, 2H), 5.81(s, 2H), 5.15 - 5.04 (m, 1H), 4.13 (dd, J = 34.3, 17.0 Hz, 2H), 3.00 - 2.81 (m, 1H), 2.70 - 2.54 (m, 1H), 2.38 - 2.19 (m, 1H), 2.11 - 1.96 (m, 1H). 19 F NMR(282 MHz, DMSO- d6) δ (ppm) -113.63 (dd, J = 11.1, 8.3 Hz,1F). ESIMS calculated for C 13 H 11 FN3O([MH] - ) 276.08, found 276.05
[0072] (Synthesis of Cl-lenalidomide) It was synthesized by the following procedure.
[0073] [ka]
[0074] 2.1 g (6.7 mmol) of methyl 2-(bromomethyl)-5-chloro-3-nitrobenzoate (see Wang, Bing; Chu, Daniel, PCT Int. Appl. (2011), WO 2011130661 A1) and 1.3 g (8.1 mmol) of 3-aminopiperidine-2,6-dione hydrochloride were dissolved in 7.0 mL of N,N-dimethylformamide, followed by addition of 1.1 mL (8.1 mmol) of triethylamine and stirring at 60 °C for 19 hours. After cooling to room temperature, water was added and the precipitate was filtered. The resulting solid was dried under reduced pressure to give 1.0 g of 3-(6-chloro-4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione in a yield of 49%. The compound data for 3-(6-chloro-4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione is shown below. mp:253.3-254.1℃. 1 H NMR (300 MHz, DMSO-d6) δ:11.08 (s, 1H), 8.52 (d, J = 1.8 Hz, 1H), 8.28 (d, J = 1.6 Hz,1H), 5.20 (dd, J = 13.3, 5.1 Hz, 1H), 4.85 (dd, J = 34.6, 19.3Hz, 2H), 2.99-2.87 (m, 1H), 2.74-2.56 (m, 2H), 2.05-1.99 (m, 1H) ppm. 13 CNMR (176 MHz, DMSO-d6) δ: 172.8, 170.6, 164.8, 143.9, 136.2, 136.1, 134.3,129.3 (d, J = 26.8 Hz), 126.8 (d, J = 31.8 Hz), 52.0, 48.4, 31.2,22.2 ppm. ATR-FTIR (KBr): ν = 3087, 1691, 1537, 1450, 1353, 1322, 1192, 889, 731, 531 cm -1 .HRMS (ESI + ): m / z calcd for C13H9ClN3O5[MH] -: 322.0236 found: 322.0234.
[0075] [ka]
[0076] 1.0 g (3.1 mmol) of 3-(6-chloro-4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione, 1.3 g (23.5 mmol) of iron, and 1.3 g (24.7 mmol) of ammonium chloride were dissolved in 39 mL of ethanol and 1.2 mL of water, and the mixture was refluxed for 16 hours. The mixture was cooled to room temperature, the solid was removed by filtration, and the filtrate was evaporated under reduced pressure. The product was purified by recrystallization from ethanol to give 526 mg of 3-(4-amino-6-chloro-1-oxoisoindolin-2-yl)piperidine-2,6-dione in 58% yield. The compound data for 3-(4-amino-6-chloro-1-oxoisoindolin-2-yl)piperidine-2,6-dione are shown below. mp:242.7-243.7 °C. 1 H NMR (500 MHz, DMSO-d6) δ:10.98 (s), 6.81 (d, J = 1.8 Hz), 6.77 (d, J = 1.8 Hz), 5.76 (s),5.05 (dd, J = 13.1, 5.2 Hz), 4.18-4.04 (m), 2.91-2.83 (m), 2.59-2.54(m), 2.29-2.20 (m), 2.04-1.97 (m) ppm. 13 ATR-FTIR (KBr): ν = 3455, 3347, 3036, 2847, 1685, 1671, 1487,1356, 1029, 957 cm -1 .HRMS (ESI +): m / z calcd for C13H11ClN3O3 [MH] - : 292.0494 found: 292.0487.
[0077] (Synthesis of Br-lenalidomide) It was synthesized by the following procedure.
[0078] [ka]
[0079] Methyl 5-bromo-2-(bromomethyl)-3-nitrobenzoate (Hayashi, Kazuya; Yamashiro, Yoshiko; Taya, Kyoko; Fukuyama, Hiroko; Todo, Yozo, PCT Int. Appl. (1999), WO9907682) 1.0 g (2.8 mmol) and 3-aminopiperidine-2,6-dione hydrochloride 560 mg (3.4 mmol) were dissolved in N,N-dimethylformamide 3.9 mL, and potassium carbonate 979 mg (7.1 mmol) was added and stirred at 50 °C for 2 hours. After cooling to room temperature, water was added and the precipitate was collected by filtration. The obtained solid was dried under reduced pressure to obtain 3-(6-bromo-4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione in a yield of 564 mg and 54%. The compound data for 3-(6-bromo-4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione is shown below. mp: 226.6-227.6 °C. 1 H NMR (300 MHz, DMSO-d6) δ:11.06 (s, 1H), 8.59 (d, J = 1.5 Hz, 1H), 8.37 (d, J = 1.5 Hz,1H), 5.21-5.15 (m, 1H), 4.81 (dd, J = 34.3, 19.3 Hz, 2H), 2.97-2.87 (m,1H), 2.72-2.62 (m, 2H), 2.03-1.99 (m, 1H) ppm. 13C NMR (176 MHz,DMSO-d6) δ: 172.8, 170.6, 164.7, 144.0, 136.4 (d, J =20.1 Hz), 132.0, 129.4, 121.8, 52.0, 48.4, 31.1, 22.2 ppm. ATR-FTIR (KBr): ν =3208, 3108, 3074, 1711, 1532, 1442, 1354, 1209, 1182, 720 cm -1 .HRMS (ESI + ): m / z calcd for C13H9BrN3O5 [MH] - :365.9731 found: 365.9723.
[0080] [ka]
[0081] 200 mg (0.54 mmol) of 3-(6-bromo-4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione, 231 mg (4.1 mmol), and 233 mg (4.4 mmol) of ammonium chloride were dissolved in 0.8 mL of ethanol and 1.4 mL of water, and the mixture was stirred at 60 °C for 2 hours. The mixture was cooled to room temperature, the solid was removed by filtration, and the filtrate was evaporated under reduced pressure. Extraction was performed using ethyl acetate, and the organic layer was washed with saturated saline and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to give 3-(4-amino-6-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione in a yield of 36.6 mg and 20%. The compound data for 3-(4-amino-6-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione is shown below. mp: 237.9-238.7 °C. 1H NMR (300 MHz, DMSO-d6) δ:11.03 (s, 1H), 6.97-6.95 (m, 2H), 5.80 (s, 2H), 5.12- 5.06 (m, 1H), 4.12 (dd, J= 35.5, 17.6 Hz, 2H), 2.95-2.87 (m, 1H), 2.73-2.63 (m, 2H), 2.05-1.99 (m, 1H)ppm. 13 C NMR (176 MHz, DMSO-d6) δ: 172.9, 171.1,167.5, 145.4, 134.2, 124.9, 121.7, 118.0, 112.4, 51.7, 45.6, 39.5, 31.2, 22.7ppm. ATR-FTIR (KBr): ν = 3425, 2186, 3083, 1681, 1605, 1481, 1462, 1335, 1199, 1026 cm -1 .HRMS (ESI + ): m / z calcd for C13H11BrN3O3 [MH] - : 335.9989 found: 335.9974.
[0082] (Synthesis of F3C-lenalidomide) It was synthesized by the following procedure.
[0083] [ka]
[0084] 2-Methyl-3-nitro-5-(trifluoromethyl)benzoic acid (References: Kuntz, Kevin Wayne; Olhava, Edward James; Chesworth, Richard; Duncan, Kenneth William, WO 2012118812 A2) 1.1g (4.4 mmol) was dissolved in 44 mL of methanol, and 1.0 mL (13.2 mmol) of thionyl chloride was slowly added dropwise. The reaction solution was then refluxed for 12 hours. The mixture was cooled to room temperature, and water and 1 mol / L aqueous sodium hydroxide solution were added, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain methyl 2-methyl-3-nitro-5-(trifluoromethyl)benzoate in a yield of 939 mg and 78%. The compound data for methyl 2-methyl-3-nitro-5-(trifluoromethyl)benzoate are shown below. 1 H NMR (300 MHz, CDCl3)δ 8.27 (s, 1H), 8.11 (s, 1H), 3.98 (s, 3H), 2.70 (s, 3H) ppm. 19 F NMR (282 MHz, CDCl3)δ -63.46 (s, 3F) ppm.
[0085] [ka]
[0086] Methyl 2-methyl-3-nitro-5-(trifluoromethyl)benzoate (646 mg, 3.2 mmol) and N-bromosuccinimide (1.1 g, 6.3 mmol) were dissolved in 4.5 mL of degassed carbon tetrachloride, and 75% benzoyl peroxide (102 mg, 0.32 mmol) was added. The reaction solution was then refluxed for 14 hours. The mixture was cooled to room temperature, and the by-products were removed by filtration, and the filtrate was distilled under reduced pressure. The resulting mixture was purified by silica gel column chromatography to obtain methyl 2-(bromomethyl)-3-nitro-5-(trifluoromethyl)benzoate (734 mg, 68% yield). The compound data for methyl 2-(bromomethyl)-3-nitro-5-(trifluoromethyl)benzoate are shown below. 1H NMR (300 MHz, CDCl3)δ 8.36 (s, 1H), 8.21 (s, 1H), 5.18 (s, 2H), 4.04 (s, 3H) ppm. 19 F NMR (282 MHz, CDCl3)δ -63.74 (s, 3F) ppm.
[0087] [ka]
[0088] 600 mg (1.8 mmol) of methyl 2-(bromomethyl)-3-nitro-5-(trifluoromethyl)benzoate and 346 mg (2.1 mmol) of 3-aminopiperidine-2,6-dione hydrochloride were dissolved in 1.8 mL of N,N-dimethylformamide, and then 0.5 mL (3.5 mmol) of triethylamine was added and stirred at 50 °C for 14 hours. After cooling to room temperature, water was added and the precipitate was collected by filtration. The obtained solid was washed with methanol and tetrahydrofuran and dried under reduced pressure to obtain 3-(4-nitro-1-oxo-6-(trifluoromethyl)isoindolin-2-yl)piperidine-2,6-dione in a yield of 197 mg and 31%. The compound data for 3-(4-nitro-1-oxo-6-(trifluoromethyl)isoindolin-2-yl)piperidine-2,6-dione are shown below. 1 H NMR (300 MHz, DMSO-d6)δ 11.08 (s, 1H), 8.71 (s, 1H), 8.52 (s, 1H), 5.23 (dd, J = 12.9, 5.0 Hz,1H), 4.96 (dd, J = 33.7, 19.9 Hz, 2H), 2.86-2.98 (m, 1H), 2.54-2.63 (m,2H), 2.03 (m, J = 5.1 Hz, 1H) ppm. 19 F NMR (282 MHz, DMSO-d6)δ -60.46 (s, 3F) ppm.
[0089] [ka]
[0090] 100 mg (0.29 mmol) of 3-(4-nitro-1-oxo-6-(trifluoromethyl)isoindolin-2-yl)piperidine-2,6-dione and 20 mg of palladium on carbon were dissolved in 10 mL of tetrahydrofuran and 10 mL of methanol. The reaction solution was degassed, and the atmosphere in the reaction vessel was replaced with hydrogen, and then the mixture was stirred at room temperature for 1 hour. The reaction solution was filtered, and the solvent was distilled off under reduced pressure to obtain 77 mg of 3-(4-amino-1-oxo-6-(trifluoromethyl)isoindolin-2-yl)piperidine-2,6-dione in 81% yield. The compound data for 3-(4-amino-1-oxo-6-(trifluoromethyl)isoindolin-2-yl)piperidine-2,6-dione are shown below. 1 H NMR (300 MHz, DMSO-d6)δ 11.22-10.84 (1H), 7.11 (s, 1H), 7.09 (s, 1H), 6.00 (s, 2H), 5.14 (dd, J= 13.2, 5.3 Hz, 1H), 4.24 (dd, J = 36.3, 17.7 Hz, 2H), 2.86-2.96 (m,1H), 2.60-2.73 (m, 1H), 2.25-2.39 (m, 1H), 2.01-2.08 (m, 1H) ppm. 19 F NMR (282 MHz, DMSO-d6)δ-60.64 (s,3F) ppm.
[0091] (Synthesis of F3CO-lenalidomide) It was synthesized by the following procedure.
[0092] [ka]
[0093] 500 mg (2.3 mmol) of 2-methyl-5-(trifluoromethoxy)benzoic acid (see WO 9730989 A1) was dissolved in 5.0 mL of concentrated sulfuric acid. The reaction solution was cooled to 0 °C, and 0.5 mL of fuming nitric acid was slowly added dropwise, followed by stirring at room temperature for 4 hours. The reaction solution was poured into ice water, and the resulting precipitate was filtered off. The filtered precipitate was washed with water and dried under reduced pressure to obtain 2-methyl-3-nitro-5-(trifluoromethoxy)benzoic acid as a mixture of positional isomers. The resulting mixture was used in the next step without further purification.
[0094] [ka]
[0095] 2.0 g (7.5 mmol) of 2-methyl-3-nitro-5-(trifluoromethoxy)benzoic acid was dissolved in 15 mL of methanol, and 1.6 mL (22.6 mmol) of thionyl chloride was slowly added dropwise. The reaction solution was then refluxed for 12 hours. The mixture was cooled to room temperature, and the solvent was distilled off under reduced pressure. The resulting mixture was purified by silica gel column chromatography to obtain methyl 2-methyl-3-nitro-5-(trifluoromethoxy)benzoate in a yield of 969 mg and 46%. The compound data for methyl 2-methyl-3-nitro-5-(trifluoromethoxy)benzoate are shown below. 1 H NMR (300 MHz, CDCl3)δ: 7.89 (s, 1H), 7.75 (s, 1H), 3.97 (s, 3H), 2.64 (s, 3H) ppm. 19 F NMR (282 MHz, CDCl3)δ: -58.7 (s, 1F) ppm. 13 C NMR (126 MHz, CDCl3)δ: 165.5, 152.3, 146.5 (d, J = 1.8 Hz), 134.9, 132.1, 126.3, 120.3 (q, J= 260.0 Hz), 119.6, 53.1, 16.0 ppm.
[0096] [ka]
[0097] 722 mg (2.5 mmol) of methyl 2-methyl-3-nitro-5-(trifluoromethoxy)benzoate and 893 mg (5.0 mmol) of N-bromosuccinimide were dissolved in 3.6 mL of degassed carbon tetrachloride, and 81 mg (0.25 mmol) of 75% benzoyl peroxide was added. The reaction solution was then refluxed for 14 hours. The mixture was cooled to room temperature, and the by-products were removed by filtration, and the filtrate was distilled under reduced pressure. The resulting mixture was purified by silica gel column chromatography to obtain methyl 2-(bromomethyl)-3-nitro-5-(trifluoromethoxy)benzoate in a yield of 734 mg and 68%. The compound data for methyl 2-(bromomethyl)-3-nitro-5-(trifluoromethoxy)benzoate are shown below. 1 H NMR (300 MHz, CDCl3)δ 7.97 (s, 1H), 7.84 (s, 1H), 5.14 (s, 2H), 4.03 (s, 3H) ppm. 19 F NMR (282 MHz, CDCl3)δ: -58.5 (s, 3F) ppm. 13 C NMR (126 MHz, CDCl3)δ: 164.7, 151.2, 148.4, 134.3, 131.6, 127.0, 120.4, 120.2 (q, J = 260.9Hz), 53.7, 22.0 ppm.
[0098] [ka]
[0099] 104 mg (0.28 mmol) of methyl 2-(bromomethyl)-3-nitro-5-(trifluoromethoxy)benzoate and 55 mg (0.34 mmol) of 3-aminopiperidine-2,6-dione hydrochloride were dissolved in 0.28 mL of N,N-dimethylformamide, and then 0.08 mL (0.60 mmol) of triethylamine was added and stirred at 50 °C for 14 hours. After cooling to room temperature, water was added and the precipitate was collected by filtration. The precipitate was washed with methanol and tetrahydrofuran and dried under reduced pressure to obtain 3-(4-nitro-1-oxo-6-(trifluoromethoxy)isoindolin-2-yl)piperidine-2,6-dione in a yield of 78 mg and 46%. The compound data for 3-(4-nitro-1-oxo-6-(trifluoromethoxy)isoindolin-2-yl)piperidine-2,6-dione are shown below. 1 H NMR (500 MHz, DMSO-d6)δ 11.06 (s, 1H), 8.46 (d, J = 1.5 Hz, 1H), 8.20 (d, J = 0.9 Hz,1H), 5.19 (dd, J = 13.1, 5.2 Hz, 1H), 4.88 (dd, J = 47.8, 19.4Hz, 2H), 2.95-2.87 (m, 1H), 2.73-2.53 (m, 2H), 2.05-1.99 (m, 1H) ppm. 19 F NMR (282 MHz, DMSO-d6)δ -57.0 (s, 3F) ppm. 13 C NMR (126 MHz, DMSO-d6)δ 172.8, 170.5, 164.8, 148.3, 144.1, 136.4, 122.3, 120.5, 119.9 (q, J =258.5 Hz), 52.1, 48.5, 31.1, 22.1 ppm.
[0100] [ka]
[0101] 50 mg (0.13 mmol) of 3-(4-nitro-1-oxo-6-(trifluoromethoxy)isoindolin-2-yl)piperidine-2,6-dione and 10 mg of palladium on carbon were dissolved in 5.0 mL of tetrahydrofuran and 5.0 mL of methanol. The reaction solution was degassed, and the atmosphere in the reaction vessel was replaced with hydrogen, and then the mixture was stirred at room temperature for 1 hour. The reaction solution was filtered, and the solvent was distilled off under reduced pressure to obtain 16 mg of 3-(4-amino-1-oxo-6-(trifluoromethoxy)isoindolin-2-yl)piperidine-2,6-dione in a yield of 34%. The compound data for 3-(4-amino-1-oxo-6-(trifluoromethoxy)isoindolin-2-yl)piperidine-2,6-dione are shown below. 1 H NMR (500 MHz, DMSO-d6)δ: 11.02 (s, 1H), 6.75 (d, J = 0.9 Hz, 1H), 6.72 (d, J = 0.9 Hz,1H), 5.92 (s, 2H), 5.11 (dd, J = 13.1, 5.2 Hz, 1H), 4.18 (dd, J =53.7, 17.1 Hz, 2H), 2.95-2.88 (m, 1H), 2.63-2.59 (m, 1H), 2.36-2.25 (m, 1H),2.06-2.02 (m, 1H) ppm. 19 F NMR (282 MHz, DMSO-d6)δ -56.4 (s, 3F) ppm. 13 C NMR (126 MHz, DMSO-d6)δ: 172.9, 171.1, 167.7, 149.5, 145.4, 133.7, 124.6, 120.1 (q, J = 255.8Hz), 108.0, 101.7, 51.8, 45.6, 31.2, 22.7 ppm. EXAMPLES
[0102] (Confirmation of the interaction ability of lenalidomide derivatives with meta-substituted groups to IKZF1, SALL4, and PLZF) In this example, the affinity (degradation-inducing ability) of lenalidomide derivatives with substituents inserted at the meta position for IKZF1, SALL4, and PLZF was confirmed by biochemical interaction analysis.
[0103] (Experimental Method) The affinities of lenalidomide, F-lenalidomide, Cl-lenalidomide and Br-lenalidomide to IKZF1, SALL4 and PLZF were calculated as relative values based on a signal value of 1 in DMSO. FLAG-GST-IKZF1, -SALL4, -PLZF, and N-terminally biotinylated bls-CRBN were synthesized as recombinant proteins using a wheat cell-free protein synthesis system. A 10-μl mixture containing 0.5 μl of the synthesized bls-CRBN was prepared in AlphaScreen buffer (100 mM Tris (pH 8.0), 0.01% Tween20, 100 mM NaCl, and 1 mg / mL BSA). A 5-μl mixture containing 0.8 μl of FLAG-GST-protein was prepared in AlphaScreen buffer. A 5-μl mixture containing DMSO (final concentration 0.5%) or thalidomide derivatives at the final concentrations shown in Figure 7 was prepared in AlphaScreen buffer. The three mixtures were then mixed in a 384-well AlphaPlate (PerkinElmer) and left to stand at 26°C for 1 h. Next, 5 μl of detection mixture containing 0.2 μg / ml anti-DYKDDDDK antibody (FUJIFILM WakoPure Chemical), 0.08 μl of streptavidin donor beads (PerkinElmer) and 0.08 μL of protein A acceptor beads (PerkinElmer) was prepared in AlphaScreen buffer. 5 μl of detection mixture was added to each well and incubated at 26°C for 1 hour, after which luminescence signals were detected using an Envision plate reader (PerkinElmer).
[0104] The affinities of F3C-lenalidomide, F3CO-lenalidomide, pomalidomide, and lenalidomide to IKZF1, SALL4, and PLZF were calculated as follows. FLAG-GST-IKZF1, -SALL4, -PLZF, and N-terminally biotinylated bls-CRBN were synthesized as recombinant proteins using a wheat cell-free protein synthesis system. A 10-μl mixture containing 0.5 μl of the synthesized bls-CRBN was prepared in AlphaScreen buffer (100 mM Tris (pH 8.0), 0.01% Tween20, 100 mM NaCl, and 1 mg / mL BSA). A 5-μl mixture containing 0.8 μl of FLAG-GST-protein was prepared in AlphaScreen buffer. A 5-μl mixture containing DMSO (final concentration 0.5%) or 10 μM thalidomide derivative was prepared in AlphaScreen buffer. The three mixtures were then mixed in a 384-well AlphaPlate (PerkinElmer) and incubated at 26°C for 1 h. Next, 5 μl of detection mixture containing 0.2 μg / ml of anti-DYKDDDDK antibody (FUJIFILM WakoPure Chemical), 0.08 μl of streptavidin donor beads (PerkinElmer), and 0.08 μl of protein A acceptor beads (PerkinElmer) was prepared in AlphaScreen buffer. 5 μl of detection mixture was added to each well, and the plate was incubated at 26°C for 1 hour, after which the luminescence signal was detected using an Envision plate reader (PerkinElmer).
[0105] 7, it was confirmed that lenalidomide, F-lenalidomide, Cl-lenalidomide, and Br-lenalidomide have low affinity for SALL4 and PLZF, and that Cl-lenalidomide and Br-lenalidomide hardly interact with SALL4 or PLZF. The results in FIG. 8 confirmed that the affinity of F3C-lenalidomide and F3CO-lenalidomide for SALL4 and PLZF was significantly lower than the affinity of lenalidomide for SALL4 and PLZF. EXAMPLES
[0106] (Confirmation of the binding ability of lenalidomide derivatives with substituents inserted at each meta position to CRBN) In this example, the binding ability of lenalidomide derivatives with substituents inserted at each meta position to CRBN was confirmed using thalidomide-immobilized beads (see Figure 9(1)).
[0107] (Experimental Method) Thalidomide derivative for immobilization (Thalidomide-O-COOH) was purchased from MedChemExpress, and magnetic beads (FG-beads) for immobilization were purchased from Tamagawa Seiki. 4 mM Thalidomide-O-COOH was immobilized on FG-beads using Tamagawa Seiki's standard protocol. FLAG-GST-CRBN was also synthesized using a wheat cell-free protein synthesis system. 50 μl of FLAG-GST-CRBN was added to 50 μl of 4 mM thalidomide-immobilized beads, and the volume was adjusted to 500 μl with IP Lysis buffer (Pierce) (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mMEDTA, 1% NP-40, 5% glycerol). After rotation at room temperature for 2 hours, the mixture was washed four times with 800 μl of IP Lysis buffer (Pierce). Equivalent amounts were then dispensed into seven tubes, and 20 μl of IP Lysis buffer (Pierce) containing 200 μM of each lenalidomide derivative was added and vortexed at room temperature for 30 minutes for competitive elution. Then, 20 μl of 2×SDS sample buffer was added to each eluted sample and boiled. Next, after electrophoresis using polyacrylamide gel, immunoblot was performed and each protein was detected using the antibodies shown in Figure 9.
[0108] (result) The results in Figure 9(2) confirmed that F-lenalidomide, Cl-lenalidomide, Br-lenalidomide, F3C-lenalidomide and F3CO-lenalidomide have the same level of interaction with CRBN (binding ability to CRBN) as lenalidomide. EXAMPLES
[0109] (Confirmation of intrinsic proteolysis in cultured cells of lenalidomide derivatives with substituents inserted at each meta position) In this example, the intrinsic proteolytic ability of cultured cells of lenalidomide derivatives with substituents inserted at each meta position was confirmed. The details are as follows.
[0110] (Experimental Method) MM1.S cultured cells were seeded in a 24-well cell culture plate (BD Falcon), and treated with DMSO (0.1%) or the lenalidomide derivatives at the concentrations shown in Figure 10. The cells were then cultured for 24 hours at 37°C and 5% CO2. The cells were then collected by pipetting, centrifuged at 900×g for 3 minutes, and the supernatant was removed using an aspirator. After washing, 500 μl of 1×PBS was added to the cell pellet, and the cells were centrifuged again at 900×g for 3 minutes, and the supernatant was removed using an aspirator. Next, 100 μl of RIPA buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1mM EDTA) containing a protease inhibitor cocktail (Sigma Aldrich) was added to the cell pellet to dissolve the cells. After centrifugation at 16,100×g for 15 minutes, the supernatant was obtained as a cell extract. Protein quantification was performed using a BCA assay kit (Thermo Fisher Scientific), and the samples were adjusted to equal protein concentrations in 1×SDS sample buffer and boiled at 95°C for 5 minutes. After electrophoresis using polyacrylamide gel, immunoblot was performed and each protein was detected using the antibodies shown in Figure 10. HuH-7 and MCF7 cultured cells were seeded in a 24-well cell culture plate (BD Falcon) and cultured for 24 hours at 37°C and 5% CO2. Next, DMSO (0.1%) or the lenalidomide derivatives at the concentrations shown in Figure 10 were administered and cultured for 24 hours at 37°C and 5% CO2. The medium supernatant was then removed with an aspirator, and the cultured cells were collected and lysed using 1x SDS sample buffer. The collected cell extract was boiled at 95°C for 5 minutes and electrophoresed using polyacrylamide gel. Next, immunoblotting was performed to detect each protein using the antibodies shown in Figure 10.
[0111] (result) The results in Figure 10 are as follows: We confirmed that F-lenalidomide and Cl-lenalidomide have the ability to induce degradation of the drug target (IKZF1 / 3·CK1α) in cell culture, but have low ability to induce degradation of the teratogenic protein SALL4·PLZF. On the other hand, Br-Len was found to have weak degradative activity against IKZF1 / 3 in cell cultures, but had virtually no ability to induce the degradation of SALL4·PLZF, a teratogenic protein. EXAMPLES
[0112] (Confirmation of anticancer activity of lenalidomide derivatives with substituents at each meta position against multiple myeloma cultured cells) In this example, the anticancer activity of lenalidomide derivatives with substituents inserted at each meta position against cultured cells derived from multiple myeloma was confirmed. The details are as follows.
[0113] (Experimental Method) MM1.S or U266 cultured cells were seeded in a 24-well cell culture plate (BD Falcon), and administered with DMSO (0.1%) or the lenalidomide derivatives at the concentrations shown in Figure 11, and cultured for 72 hours at 37°C and 5% CO2. One-third of the cells were collected by pipetting, centrifuged at 200 x g for 3 minutes, and the supernatant was removed with an aspirator. The cell pellet was then resuspended in medium, administered with DMSO (0.1%) or the lenalidomide derivatives at the concentrations shown in Figure 11, and cultured for 72 hours at 37°C and 5% CO2. As described above, the cells were cultured in fresh medium containing DMSO or lenalidomide derivatives every 3 days for a total of 9 days. After that, the cells were suspended and added 40 μl to a 96-well opti-plate (PerkinElmer), and 40 μl of Cell Titer-Glo kit (Promega) was added to each well to lyse the cells. The luminescence signal was then detected using SpectraMax iD3 (Molecular devise).
[0114] (result) The results in FIG. 11 are as follows: It was confirmed that the proliferation-inhibitory effect of F-lenalidomide on cultured multiple myeloma cells (anti-cancer cell proliferation effect) is comparable to the anti-proliferative effects of pomalidomide and lenalidomide, which are active ingredients in known multiple myeloma therapeutics. It was also confirmed that Cl-lenalidomide has an anti-proliferative effect, although it is weaker than those of pomalidomide and lenalidomide. EXAMPLES
[0115] (Confirmation of anticancer activity of lenalidomide derivatives with substitutions at meta positions against chromosome 5 deletion myelodysplastic syndrome) In this example, the anticancer activity of lenalidomide derivatives with substituents inserted at each meta position against cultured cells derived from chromosome 5 deletion myelodysplastic syndrome was confirmed. The details are as follows.
[0116] (Experimental Method) MDS-L cultured cells were seeded in a 24-well cell culture plate (BD Falcon), and administered with DMSO (0.1%) or the lenalidomide derivatives at the concentrations shown in Figure 12, and cultured for 96 hours at 37°C and 5% CO2. Half the amount of cells was collected by pipetting, centrifuged at 200 x g for 3 minutes, and the supernatant was removed with an aspirator. The cell pellet was then resuspended in medium, and administered with DMSO (0.1%) or the lenalidomide derivatives at the concentrations shown in Figure 12, and cultured for 96 hours at 37°C and 5% CO2. As described above, the cells were cultured in fresh medium containing DMSO or lenalidomide derivatives every 4 days for a total of 20 days. After that, the cells were suspended and added to a 96-well opti-plate (PerkinElmer) at 40 μl each, and 40 μl of Cell Titer-Glo kit (Promega) was added to each well to lyse the cells. The luminescence signal was then detected using SpectraMax iD3 (Molecular devise).
[0117] (result) The results in FIG. 12 are as follows: It was confirmed that F-lenalidomide has a stronger ability to inhibit the proliferation of cultured cells of chromosome 5-deficient myelodysplastic syndrome (anti-cancer cell proliferation effect) than the anti-proliferative effect of lenalidomide, the active ingredient of a known therapeutic agent for chromosome 5-deficient myelodysplastic syndrome. It was also confirmed that Cl-lenalidomide has the same level of anti-proliferative effect as lenalidomide. Thus, the present invention covers therapeutic agents for chromosome 5-deficient myelodysplastic syndrome, which contain F-Len or Cl-Len. EXAMPLES
[0118] Confirmation of Neoproteolysis of Known PROTACs In this example, the neoprotein degradation abilities of known PROTACs dBET1 and ARV-825 were confirmed. Details are as follows.
[0119] (Experimental Method) MM1.S cells were seeded in a 24-well cell culture plate (BD Falcon) and treated with DMSO (0.1%), 20 μM thalidomide, 10 μM lenalidomide, 1 μM pomalidomide, 20 μM 5-hydroxythalidomide, 1 μM dBET1, or 1 μM ARV-825. The cells were then cultured at 37°C, 5% CO2 for 24 hours. The cells were then collected by pipetting and centrifuged at 900×g for 3 minutes, after which the supernatant was removed using an aspirator. After washing, 500 μl of 1×PBS was added to the cell pellet, followed by centrifugation at 900×g for 3 minutes, and the supernatant was removed using an aspirator. Next, 100 μl of RIPA buffer containing a protease inhibitor cocktail (Sigma Aldrich) was added to the cell pellet to dissolve the cells. After centrifugation at 16,100×g for 15 minutes, the supernatant was obtained as a cell extract. Protein quantification was performed using a BCA assay kit (Thermo Fisher Scientific), and the samples were adjusted to equal protein concentrations in 1×SDS sample buffer and boiled at 95°C for 5 minutes. After electrophoresis using polyacrylamide gel, immunoblot was performed and each protein was detected using the antibodies shown in Figure 13. HuH-7 cultured cells were seeded in a 24-well cell culture plate (BD Falcon) and cultured for 24 hours at 37°C and 5% CO2. Then, DMSO (0.1%), 20 μM thalidomide, 10 μM lenalidomide, 1 μM pomalidomide, 20 μM 5-hydroxythalidomide, 1 μM dBET1, or 1 μM ARV-825 were administered and cultured for 24 hours at 37°C and 5% CO2. After that, the medium supernatant was removed with an aspirator, and the cultured cells were collected and lysed using 1×SDS sample buffer. The collected cell extract was boiled at 95°C for 5 minutes and electrophoresed using polyacrylamide gel. Next, immunoblot was performed and each protein was detected using the antibodies shown in Figure 13. MM1.S cells were seeded in a 24-well cell culture plate (BD Falcon) and treated with DMSO (0.1%), 10 μM thalidomide, 1 μM lenalidomide, 0.1 μM pomalidomide, 10 μM dBET1 or 0.1 μM ARV-825. The cells were then suspended and added to a 96-well opti-plate (PerkinElmer) in 40 μl portions, and 40 μl of Cell Titer-Glo kit (Promega) was added to each well to lyse the cells. The luminescence signal was then detected using a SpectraMax iD3 (Moleculardevise).
[0120] (result) The results in FIG. 13 are as follows: We confirmed that dBET1 has low ability to induce degradation of the teratogenic proteins SALL4 and PLZF, but also low ability to induce degradation of the drug targets IKZF1 and IKZF3. In other words, we confirmed the problem that dBET1 has low anti-cancer cell proliferation effect. We confirmed that ARV-825 has a high ability to induce the degradation of IKZF1 and IKZF3, but also has a high ability to induce the degradation of SALL4 and PLZF. In other words, we confirmed the problem that ARV-825 cannot be applied to cancer treatment where teratogenicity is an issue. That is, it was confirmed that known PROTACs induce degradation of not only the target protein but also the neo-substrate of E3 binder or have teratogenicity problems. EXAMPLES
[0121] (Target protein degradation-inducing compound of the present invention) From the results of Examples 1 to 10, the following was confirmed. Lenalidomide, F-lenalidomide and Cl-lenalidomide, which degrade both IKZF1 / 3 / CK1α, a neo-substrate of E3 binder, and target proteins, are thought to be cerebron binders, target protein degradation-inducing compounds that are effective against blood cancers (see Figure 14, left), as confirmed in the following examples. Cl-lenalidomide, which only degrades target proteins and has low ability to induce degradation of neosubstrates, and Br-lenalidomide, F3C-lenalidomide and F3CO-lenalidomide, which have no ability to induce degradation of neosubstrates, have low or no ability to induce degradation of IKZF1 / 3 / CK1α, a neosubstrate of E3 binder, and therefore can be used for diseases other than specific cancers.Furthermore, since they avoid or reduce teratogenicity, they are thought to be cerebron binders, target protein degradation-inducing compounds that can be used for a variety of cancers (see Figure 14, right), as confirmed in the following examples. EXAMPLES
[0122] (Synthesis of target protein degradation-inducing compound of the present invention) In this example, the target protein decomposition-inducing compound of the present invention shown in Figure 15 was synthesized. Details are as follows. Commercially available ARV-825 and dBET1 were used.
[0123] Synthesis of (Lenalidomide-Linker-Birabresib) The synthesis of Lenalidomide-Linker-JQ-1 derivative (1a) was carried out as follows.
[0124] [ka]
[0125] The synthesis of 3-(4-((2-(2-(2-(2-(4-nitrophenoxy)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (3a) was carried out as follows.
[0126] [ka]
[0127] Lenalidomide (44.6 mg, 0.172 mmol, 1.0 equiv), 2 (87.7 mg, 0.206 mmol, 1.2 equiv), DMF (0.1 M, 2 mL), and N,N-diisopropylethylamine (87.8 μL, 0.516 mmol, 3.0 equiv) were added to a 10 mL recovery flask under a nitrogen atmosphere, and the mixture was stirred at 100 °C for 12 h. After cooling to room temperature, the mixture was azeotroped with toluene under reduced pressure to remove the solvent. The crude product was purified by silica gel chromatography (dichloromethane:methanol = 1 / 0 → 20 / 1). As multiple spots were observed, the product was purified again by silica gel chromatography (ethyl acetate) to obtain compound 3a (39.2 mg, 41% yield). 1 H NMR(300MHz, CDCl3) δ: 8.51 (s, 1H), 8.18 (tlike, J = 9.1 Hz, 2H), 7.34 (t like, J = 7.8 Hz, 1H), 7.00-6.92(m, 2H), 6.78 (d, J = 7.9 Hz, 1H), 5.21 (dd, J = 13.0, 5.1 Hz,1H), 4.26-4.12 (m, 4H), 3.91-3.84 (m, 2H), 3.76-3.56 (m, 12H), 3.45-3.39 (m,2H), 2.94-2.73 (m, 1H), 2.35-2.12 (m, 2H)
[0128] The synthesis of 1a was carried out as follows.
[0129] [ka]
[0130] The nitro group of the synthesized 3a was reduced. 3a (39.8 mg, 0.0715 mmol, 1.0 equiv), iron (39.9 mg, 0.715 mmol, 10 equiv) were added to ethanol (1.0 ml, 0.072 M), and then ammonium chloride (38.3 mg, 0.715 mmol, 10 equiv) dissolved in water (0.5 ml, 0.14 M) was added. The mixture was then heated to 80 °C and stirred for 2 hours. After cooling to room temperature, it was filtered and washed with ethyl acetate. Ethyl acetate and water were added to the filtrate, and the organic layer was washed with saturated saline and dehydrated with sodium sulfate. The solvent was then removed under reduced pressure to obtain the amine (4a below). This was used in the next step without further purification.
[0131] [ka]
[0132] Next, the amine was condensed with JQ-1. Under a nitrogen atmosphere, the amine (17.2 mg, 0.0327 mmol, 1.0 equiv), JQ-1 (13.1 mg, 0.0327 mmol, 1.0 equiv), and HATU (18.6 mg, 0.0491 mmol, 1.5 equiv) were dissolved in DMF (0.5 mL, 0.065 M), and N,N-Diisopropylethylamine (31.1 μL, 0183 mmol, 5.6 equiv) was added. The mixture was then stirred at room temperature for 12 hours. The reaction solution was filtered and then isolated by HPLC under the conditions described below. NOMURA CHEMICAL DevelosilODS-HG-5, 20 × 250 mm, CH3CN / H2O = 10 / 90 to 40 / 60 with 0.1% TFA, flow rate 5.0 mL / min, measurement wavelength = 220 nm, tR = 53.6 min. The developing solvent was removed under reduced pressure to obtain 9.5 mg of a yellow solid 1a in a 14% yield (2 steps). 1H NMR(300MHz, CD3OD) δ: 10.11 (s, 1H), 7.49 - 7.38(m, 6H), 7.32 (t-like, J = 7.8 Hz, 1H), 7.10 (d, J = 7.3 Hz, 1H),6.87 (d, J = 8.8 Hz, 2H), 5.01 - 4.85 (m, 2H), 5.12 (dd, J = 13.3, 4.8 Hz, 1H), 4.73 (dd, J = 8.5, 5.9 Hz, 1H), 4.29 (s, 2H), 4.08 - 4.05 (m, 2H), 3.80 - 3,77(m, 2H), 3.71 - 3.64 (m,10H), 3.44 - 3.37 (m, 2H),2.95 - 2.75 (m, 2H), 2.72 (s,3H), 2.45 (s, 3H), 2.40 - 2.34(m, 1H), 2.14 - 2.10 (m, 1H)1.69 (s, 3H) ppm. HRMS (ESI) calcd.for C 46 H 50 N8O8SCl [M + H] + :909.3160 found 909.3141.
[0133] Synthesis of ("F-lenalidomide" - "Linker" - "Birabresib") The synthesis of the Fluorolenalidomide-Linker-JQ-1 derivative (1b) was carried out as follows.
[0134] [ka]
[0135] Synthesis of 3-(6-fluoro-4-((2-(2-(2-(2-(4-nitrophenoxy)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione(3b)
[0136] [ka]
[0137] Under a nitrogen atmosphere, 6-fluorolenalidomide (50 mg, 0.180 mmol, 1.0 equiv), 2 (92.0 mg, 0.216 mmol, 1.2 equiv), DMF (0.1 M, 2 mL), and N,N-diisopropylethylamine (92 μL, 0.540 mmol, 3.0 equiv) were added in this order to a 10 mL recovery flask, and the mixture was stirred at 100 °C for 12 h. After cooling to room temperature, the mixture was azeotroped with toluene under reduced pressure to remove the solvent. The resulting crude product was purified by silica gel chromatography (ethyl acetate:methanol = 1 / 0 → 20 / 1). The solvent was removed under reduced pressure to give compound 3b (36.9 mg, 36% yield). 1 H NMR (300MHz, CDCl3) δ: 8.24-8.13 (m, 3H), 7.03-6.92 (m, 3H), 6.50(dd, J = 11.4, 2.1 Hz, 1H), 5.23 (dd, J = 13.0, 5.4 Hz, 1H),4.33-4.12 (m, 4H), 3.94-3.88 (m, 2H), 3.77-3.63 (m, 10H), 3.39-3.35 (m, 2H),2.99-2.84 (m, 2H), 2.54-2.54 (m, 1H), 2.37-2.25 (m, 2H), 1.79-1.79 (m, 1H) 19 F NMR(282MHz, CDCl3) δ: -111.1 (t like, J = 9.4 Hz, 1F)
[0138] Synthesis of 1b
[0139] [ka]
[0140] The nitro group of the synthesized 3b was reduced. 3b (36.9 mg, 0.0642 mmol, 1.0 equiv), iron (35.9 mg, 0.642 mmol, 10 equiv) were added to ethanol (1.0 ml, 0.064 M), and then ammonium chloride (34.4 mg, 0.642 mmol, 10 equiv) dissolved in water (0.5 ml, 0.13 M) was added. The mixture was then heated to 80 °C and stirred for 2 h. After cooling to room temperature, it was filtered and washed with ethyl acetate. Ethyl acetate and water were added to the filtrate, and the organic layer was washed with saturated saline and dehydrated with sodium sulfate. The solvent was then removed under reduced pressure to obtain the amine form (25.8 mg, yield 74%, crude). This was used in the next step without further purification. Next, the amine compound was condensed with JQ-1. Under a nitrogen atmosphere, the amine compound (17.4 mg, 0.0314 mmol, 1.0 equiv), JQ-1 (12.6 mg, 0.0314 mmol, 1.0 equiv), and HATU (17.9 mg, 0.0471 mmol, 1.5 equiv) were dissolved in DMF (0.5 mL, 0.063 M), and N,N-Diisopropylethylamine (16.0 μL, 0.0942 mmol, 3.0 equiv) was added. The mixture was then stirred at room temperature for 15 hours. The reaction solution was filtered and then isolated by HPLC under the conditions described below. NOMURA CHEMICAL DevelosilODS-HG-5, 20 × 250 mm, CH3CN / H2O = 10 / 90 to 40 / 60 with 0.1% TFA, flow rate 5.0 mL / min, measurement wavelength = 220 nm. The developing solvent was removed under reduced pressure to give 9.5 mg of compound 1b in a yield of 33%. 1H NMR (300 MHz, CD3OD) δ: 10.11(s, 1H), 7.98 (s, 1H), 7.49 - 7.39(m, 6H), 6.87 (d, J = 9.1 Hz, 2H), 6.70 (dd, J = 7.6, 2.1 Hz,1H), 6.58 (dd, J = 12.3, 2.1 Hz, 1H), 5.10 (dd, J = 13.3, 5.4 Hz,1H), 4.79 - 4.71 (m, 1H), 4.24 (s, 2H), 4.07 (t, J = 4.5 Hz, 2H), 3.79 (t, J = 4.5 Hz, 2H),3.70 - 3.64 (m, 10H), 3.37 - 3.34 (m, 2H), 2.72 (s, 3H), 2.45(s, 3H), 1.70 (s, 3H) ppm. 19 F NMR (282 MHz, CD3OD) δ -107.8 (dd, J = 11.9, 7.9 Hz, 1F) ppm. HRMS(ESI) calcd. for C 46 H 49 N8O8FSCl [M+ H] + : 927.3067 found 927.3024.
[0141] ("Cl-レナリドミド"-"リンカー"-"Birabresib") synthesis Synthesis of Chloro lenalidomide-Linker-JQ-1 inducer (4b), following instructions.
[0142]
change
[0143] 3-(6-chloro-4-((2-(2-(2-(2-(4-nitrophenoxy)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione(3b) Lenalidomide 1b (58.7 mg, 0.200 mmol, 1.0 equiv), 2 (340.2 mg, 0.800 mmol, 4.0 equiv), DMF (0.2 M, 1.0 mL), and N,N-Diisopropylethylamine (0.10 mL, 0.600 mmol, 3.0 equiv) were added to a 10 mL recovery flask under nitrogen atmosphere and stirred at 110 °C for 24 h. The solvent was then removed under reduced pressure, and the resulting crude product was purified by silica gel chromatography (ethyl acetate:methanol = 20 / 1) to give compound 3b (58.5 mg, 49% yield). 1 H NMR (300MHz, CDCl3) δ: 8.55(s, 1H), 8.15 (d, J = 12.1 Hz, 2H), 7.16 (s, 1H), 6.92 (d, J =12.2 Hz, 2H), 6.69 (s, 1H), 5.15 (dd, J = 12.9, 5.3 Hz, 1H), 4.33 (s,1H), 4.07-4.26 (m, 4H), 3.84 (t, J = 4.6 Hz, 2H), 3.54-3.74 (m, 10H),3.33 (d like, J = 4.1 Hz, 2H), 2.71-2.87 (m, 2H), 2.10-2.30 (m, 2H)
[0144] 3-(4-((2-(2-(2-(2-(4-aminophenoxy)ethoxy)ethoxy)ethoxy)ethyl)amino)-6-chloro-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3b (58.5 mg, 0.099 mmol, 1.0 equiv), iron (55.2 mg, 0.990 mmol, 10 equiv) were added to ethanol (1.7 ml), followed by the addition of ammonium chloride (53.0 mg, 0.990 mmol, 10 equiv) dissolved in water (0.4 ml). The mixture was then heated to 80 °C and stirred for 1 h. After cooling to room temperature, it was filtered and washed with ethyl acetate. Ethyl acetate and water were added to the filtrate, and the organic layer was washed with saturated saline and dehydrated over sodium sulfate. The solvent was then removed under reduced pressure to obtain the reduced product. This was used in the next step without further purification. The above-mentioned reduced product (46.8 mg, 0.0834 mmol, 1.0 equiv), JQ-1 (33.3 mg, 0.0834 mmol, 1.0 equiv), and HATU (63.1 mg, 0.166 mmol, 2.0 equiv) were dissolved in DMF (0.8 mL, 0.1M) at 0 °C under a nitrogen atmosphere, and N,N-Diisopropylethylamine (43.0 μL, 0.250 mmol, 3.0 equiv) was added and stirred at room temperature for 1 hour. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over sodium sulfate. Isolation was performed by HPLC under the conditions described below. NOMURA CHEMICAL Develosil ODS-HG-5, 20 × 250mm, CH3CN / H2O = 10 / 90 to 60 / 40 with 0.1% TFA, flow rate 5.0 mL / min, measurement wavelength = 220 nm, t R = 69.6 min. The developing solvent was removed under reduced pressure to give 64.0 mg of a yellow solid 4b in 81% yield (2 steps). 1H NMR (300 MHz, CD3OD) δ: 7.30-7.59(m, 6H), 6.93-7.02 (m, 1H), 6.78-6.85 (m, 3H), 5.06 (dd, J = 13.2, 5.0Hz, 1H), 4.75-4.84 (m, 1H), 4.15-4.28 (m, 2H), 4.02-4.09 (m, 2H), 3.75-3.85 (m,2H), 3.48-3.68 (m, 12H), 3.19-3.35 (m, 4H), 2.67-2.89 (m, 5H), 2.22-2.48 (m,4H), 2.01-2.11 (m, 1H), 1.59-1.74 (m, 3H)
[0145] Synthesis of ("F3C-Lenalidomide" - "Linker" - "Birabresib") The synthesis of trifluoromethyl lenalidomide-Linker-JQ-1 derivative (4a) was carried out as follows.
[0146] [ka]
[0147] 3-(4-((2-(2-(2-(2-(2-(4-nitrophenoxy)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxo-6-(trifluoromethyl)isoindolin-2-yl)piperidine-2,6-dione(3a) Lenalidomide 1a (65.5 mg, 0.200 mmol, 1.0 equiv), 2 (255.1 mg, 0.600 mmol, 3.0 equiv), NMP (0.2 M, 1.0 mL), and N,N-Diisopropylethylamine (0.10 mL, 0.600 mmol, 3.0 equiv) were added to a 10 mL recovery flask under nitrogen atmosphere and stirred at 110 °C for 12 h. The solvent was then removed under reduced pressure at 50 °C. The crude product was purified by silica gel chromatography (ethyl acetate:methanol = 1 / 0 → 5 / 1) to give compound 3a (46.3 mg, 41% yield). 1 H NMR (300MHz, CDCl3) δ: 8.71 (s, 1H), 8.10-8.15 (m, 2H), 7.44 (s, 1H), 6.90-6.98 (m, 3H),5.18 (dd, J = 12.9, 5.3 Hz, 1H), 4.49 (s, 1H), 4.15-4.35 (m, 4H), 3.84(t, J = 4.6 Hz, 2H), 3.74 (t, J = 4.9 Hz, 2H), 3.54-3.68 (m, 8H),3.37 (m, 2H), 2.71-2.85 (m, 2H), 1.98-2.39 (m, 2H) 19 F NMR(282MHz, CDCl3) δ: -62.84 (s, 3F)
[0148] 3-(4-((2-(2-(2-(2-(4-aminophenoxy)ethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxo-6-(trifluoromethyl)isoindolin-2-yl)piperidine-2,6-dione 3a (46.3 mg, 0.074 mmol, 1.0 equiv), iron (41.3 mg, 0.740 mmol, 10 equiv) were added to ethanol (1.2 ml), followed by the addition of ammonium chloride (40.0 mg, 0.740 mmol, 10 equiv) dissolved in water (0.3 ml). The mixture was then heated to 80 °C and stirred for 1 h. After cooling to room temperature, it was filtered and washed with ethyl acetate. Ethyl acetate and water were added to the filtrate, and the organic layer was washed with saturated saline and dehydrated over sodium sulfate. The solvent was then removed under reduced pressure to obtain the reduced product. This was used in the next step without further purification.
[0149] The above amine (reduced form) (37.5 mg, 0.0630 mmol, 1.0 equiv), JQ-1 (25.3 mg, 0.0630 mmol, 1.0 equiv), and HATU (47.9 mg, 0.126 mmol, 2.0 equiv) were dissolved in DMF (0.6 mL, 0.1M) at 0 °C under a nitrogen atmosphere, and N,N-Diisopropylethylamine (32.5 μL, 0.189 mmol, 3.0 equiv) was added and the mixture was stirred at room temperature for 2 hours. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline and dried over sodium sulfate. Isolation was performed by HPLC under the conditions described below. NOMURA CHEMICAL Develosil ODS-HG-5, 20 × 250mm, CH3CN / H2O = 10 / 90 to 90 / 10 with 0.1% TFA, flow rate 5.0 mL / min, measurement wavelength = 220 nm, t R = 39.5 min. The developing solvent was evaporated under reduced pressure to give a yellow solid 4a (41.0 mg, 67% yield (2 steps). 1H NMR (300MHz, CD3OD) δ:7.39-7.48 (m, 6H), 7.27 (s, 1H), 7.03 (s, 1H), 6.84 (d, J = 8.8 Hz, 2H),5.09-5.14 (m, 1H), 4.79 (d, J = 5.6 Hz, 1H), 4.33 (s, 2H), 4.04 (t, J= 4.4 Hz, 2H), 3.76-3.79 (m, 2H), 3.53-3.71 (m, 13H), 3.42 (t, J = 5.0Hz, 2H), 2.70-2.86 (m, 5H), 2.37-2.45 (m, 5H), 2.14 (s, 1H), 1.69 (s, 3H) 19 F NMR(282MHz, CDCl3) δ: -62.89 (s, 3F) EXAMPLES
[0150] (Confirmation of selectivity of the target protein degradation-inducing compound of the present invention for neo-substrates of cerebron binder) In this example, the selectivity of the following target protein degradation-inducing compounds for the neo-substrate of cerebron binder was confirmed. "Cerebron binder" - "Linker" - "Target protein binder" Le-PROTAC: Lenalidomide - Linker (see Figure 15) - Birabresib NE-005-PROTAC: "F-lenalidomide" - "Linker (see Figure 15)" - "Birabresib" NE-013-PROTAC: "Cl-lenalidomide" - "Linker (see Figure 15)" - "Birabresib" NE-015-PROTAC: "F3C-lenalidomide" - "Linker (see Figure 15)" - "Birabresib"
[0151] (Experimental Method) MM1.S or H929 cultured cells were seeded in a 24-well cell culture plate (BD falcon), and DMSO (0.1%) or drugs were administered at the concentrations shown in Figure 16, and cultured for 24 hours at 37°C, 5% CO2. The cells were then collected by pipetting, centrifuged at 900×g for 3 minutes, and the supernatant was removed with an aspirator. After that, 500 μl of 1×PBS was added to the cell pellet to wash it, and it was centrifuged again at 900×g for 3 minutes, and the supernatant was removed with an aspirator. Next, 100 μl of RIPA buffer containing a protease inhibitor cocktail (Sigma Aldrich) was added to the cell pellet to dissolve the cells. After that, the cells were centrifuged at 16,100×g for 15 minutes, and the supernatant was obtained as a cell extract. Next, protein quantification was performed using a BCA assay kit (Thermo Fisher Scientific), and the proteins were adjusted to the same protein concentration in 1×SDS sample buffer and boiled at 95°C for 5 minutes. After polyacrylamide gel electrophoresis, immunoblot was performed, and each protein was detected using the antibodies shown in FIG. MM1.S cultured cells were seeded in a 24-well cell culture plate (BD Falcon), DMSO (0.1%) or drugs (0.1 μM) were administered, and cultured for 5 days at 37°C, 5% CO2. The cells were then suspended and added to a 96-well opti-plate (PerkinElmer) at 40 μl each, and 40 μl of Cell Titer-Glo kit (Promega) was added to each well to lyse the cells. Luminescence signals were then detected using SpectraMax iD3 (Molecular devise).
[0152] (result) The results are shown in Figure 16. Unlike the known PROTAC ARV-825, the target protein degradation-inducing compound of the present invention does not induce the degradation of IKZF1 / 3 / CK1α, and therefore has the neo-substrate selectivity of cerebron binder, and further has been confirmed to have anti-cancer activity (in particular, inhibitory activity against multiple myeloma proliferation). In addition, the target protein decomposition-inducing compound of the present invention can induce the degradation of the target proteins BRD2, BRD3 and BRD4. It has been reported that BRD2-4 is involved in the proliferation of various cancer types, and it has been reported that JQ1 is effective against various cancer types including lung cancer, prostate cancer and NUT midline adenocarcinoma in addition to blood cancers such as AML, DLBCL, MM and ALL. That is, the target protein decomposition-inducing compound of the present invention has not only a multiple myeloma proliferation inhibitory effect, but also a variety of cancer cell proliferation inhibitory effect such as prostate cancer, Burkitt's lymphoma, NUT midline adenocarcinoma and lung cancer. EXAMPLES
[0153] (Confirmation of the ability of the target protein decomposition-inducing compound of the present invention to induce degradation of SALL4 and PLZF) In this example, the degradation-inducing abilities of the following target protein degradation-inducing compounds for SALL4 and PLZF were confirmed. "Cerebron binder" - "Linker" - "Target protein binder" Le-PROTAC: Lenalidomide - Linker (see Figure 15) - Birabresib F-PROTAC: "F-lenalidomide" - "Linker (see Figure 15)" - "Birabresib" Cl-PROTAC: "Cl-lenalidomide" - "Linker (see Figure 15)" - "Birabresib" F3C-PROTAC: "F3C-lenalidomide" - "Linker (see Figure 15)" - "Birabresib"
[0154] (Experimental Method) NTERA cultured cells were seeded in a 24-well cell culture plate (BD Falcon) and cultured at 37°C, 5% CO2 for 24 hours. Next, DMSO (0.1%) or drugs were administered at the concentrations shown in Figure 17, and cultured at 37°C, 5% CO2 for 24 hours. The medium supernatant was then removed with an aspirator, 500 μl of 1×PBS was added to the cell pellet for washing, and the supernatant was removed with an aspirator. Next, 100 μl of RIPA buffer containing a protease inhibitor cocktail (Sigma Aldrich) was added to the cells to dissolve them. After centrifugation at 16,100×g for 15 minutes, the supernatant was obtained as a cell extract. Next, protein quantification was performed using a BCA assay kit (Thermo Fisher Scientific), and the samples were adjusted to equal protein concentrations in 1×SDS sample buffer and boiled at 95°C for 5 minutes. After polyacrylamide gel electrophoresis, immunoblot was performed, and each protein was detected using the antibodies shown in FIG. MDS-L cultured cells were seeded in a 24-well cell culture plate (BD Falcon), and DMSO (0.1%) or drugs were administered at the concentrations shown in Figure 17, and cultured for 24 hours at 37°C and 5% CO2. The cells were then collected by pipetting, centrifuged at 900×g for 3 minutes, and the supernatant was removed using an aspirator. After that, 500 μl of 1×PBS was added to the cell pellet to wash it, and it was centrifuged again at 900×g for 3 minutes, and the supernatant was removed using an aspirator. Next, 100 μl of RIPA buffer containing a protease inhibitor cocktail (Sigma Aldrich) was added to the cell pellet to dissolve the cells. After that, the cells were centrifuged at 16,100×g for 15 minutes, and the supernatant was obtained as a cell extract. Next, protein quantification was performed using a BCA assay kit (Thermo Fisher Scientific), and the cells were adjusted to an equal protein concentration in 1×SDS sample buffer and boiled at 95°C for 5 minutes. After polyacrylamide gel electrophoresis, immunoblot was performed, and each protein was detected using the antibodies shown in FIG.
[0155] (result) The results are shown in Figure 17. It has been confirmed that the target protein decomposition-inducing compounds of the present invention (particularly Cl-PROTAC and F3C-PROTAC) do not induce the degradation of SALL4 and PLZF, unlike the known PROTAC ARV-825, and have the neo-substrate selectivity of cerebron binders. In other words, the target protein decomposition-inducing compounds of the present invention (particularly Cl-PROTAC and F3C-PROTAC) can be used for various types of cancers by using various target protein binders. EXAMPLES
[0156] (Confirmation of the anticancer effect of the target protein degradation-inducing compound of the present invention) In this example, the anticancer effects of the following target protein degradation-inducing compounds were confirmed. "Cerebron binder" - "Linker" - "Target protein binder" Le-PROTAC: Lenalidomide - Linker (see Figure 15) - Birabresib F-PROTAC: "F-lenalidomide" - "Linker (see Figure 15)" - "Birabresib" Cl-PROTAC: "Cl-lenalidomide" - "Linker (see Figure 15)" - "Birabresib" F3C-PROTAC: "F3C-lenalidomide" - "Linker (see Figure 15)" - "Birabresib"
[0157] (Experimental Method) HCT116 or NTERA cultured cells were seeded in a 96-well cell culture plate (BD Falcon), and DMSO (0.1%) or drugs were administered at the concentrations shown in Figure 18. The cells were cultured for 2 days at 37°C and 5% CO2. The culture supernatant was then removed using an aspirator, and 40 μl of culture medium was added. Next, 40 μl of Cell Titer-Glo kit (Promega) was added to each well to lyse the cells, and 40 μl of each was added to a 384-well opti-plate (PerkinElmer), and the luminescence signal was detected using SpectraMax iD3 (Molecular devise).
[0158] (result) The results are shown in Figure 18. It has been confirmed that the target protein degradation-inducing compound of the present invention is effective against solid cancers (particularly embryonal carcinoma and colon cancer). EXAMPLES
[0159] (Disassembly evaluation of SALL4 of CC-220) In this example, the decomposition of SALL4 of the following compound, CC-220, was carried out with reference to the measurement method in the above example. It was confirmed that CC-220 only weakly degrades SALL4 at concentrations that allow it to degrade IKZF1 and IKZF3 (see FIG. 19). In other words, it was confirmed that CC-220 can be an active ingredient in a composition for treating blood cancer. In addition, the following fluorinated CC-220, CC-92480, and fluorinated CC-92480, which have similar chemical structures and properties to CC-220, can also be active ingredients in the composition for treating blood cancer. In addition, CC-220, fluorinated CC-220, CC-92480 and fluorinated CC-92480 can be cerebron binders of the targeted protein degradation-inducing compound of the present invention.
[0160] [ka]
[0161] [ka]
[0162] [ka]
[0163] [ka] EXAMPLES
[0164] (Degradation ability of the target protein degradation-inducing compound and cancer therapeutic composition of the present invention) The decomposition ability of each protein of the target protein decomposition-inducing compound was calculated as shown in the table below, assuming the resolution by Len-PROTAC as 100. ○ Resolution of each protein in the cancer therapeutic composition 1) The value was converted to a value with Len set to 100. Furthermore, if the value was lower than 0, the value was set to 0. 2) The results for HuH7 cells and MM1.S cells in FIG. 10 (1 μmol / l, 10 μmol / l) were adopted, and for F3C-Len, which was not measured in FIG. 10, the results in FIG. 16 and FIG. 17 were adopted. 3) For each value, the range is set between the largest and smallest values. ○ Degradation ability of each protein of the target protein degradation-inducing compound 1) The values were converted to values with Len-PROTAC set to 100. Furthermore, if the value was lower than 0, the value was set to 0. 2) For each value, the range is between the largest and smallest values.
[0165] [Table 1]
[0166] [Table 2] EXAMPLES
[0167] (Experimental Method) To evaluate the antitumor effects of PROTACs in individual animals, we performed analysis in a mouse xenograft model using cultured neuroblastoma cells (IMR32 cells), for which multiple reports have shown that BRD2-4 is a therapeutic target. Details are as follows.
[0168] (Experimental Method) IMR32 cells were seeded onto a 10 cm cell culture dish (BD Falcon) and cultured at 37°C, 5% CO2. Then, 5 × 10 cells were seeded per nude mouse. 6 IMR32 cells were resuspended in 50 μl of PBS and mixed with 50 μl of Matrigel (Corning). 100 μl of the mixed cell solution was subcutaneously transplanted into the flank of nude mice. One week after transplantation, DMSO or PROTAC was administered intraperitoneally once a day (weekdays only). The administration solution was diluted with PBS to 10% DMSO, 5 mg / kg PROTAC, and 1% Tween 80, and 200 μl was administered intraperitoneally. Five weeks after administration, the tumor volume was measured with an electronic caliper, and the tumor was removed and photographed.
[0169] (result) The results in FIG. 33 are as follows: We confirmed that PROTACs using lenalidomide or lenalidomide derivatives suppressed tumor growth in mice. In particular, PROTACs using F3C-lenalidomide showed equal or greater tumor growth suppression effects than PROTACs using lenalidomide.
[0170] Cereblon is a component of ubiquitin ligase, which is responsible for protein degradation. When thalidomide derivative compounds bind to cereblon, their substrate specificity changes, resulting in the degradation of proteins (neo-substrates) that are not normally degraded, resulting in medicinal effects or side effects. As already mentioned, the inventors have discovered that the binding of SALL4 and PLZF to the cereblon-thalidomide derivative compound complex and the induction of its degradation is an important event in the manifestation of teratogenicity. In other words, when thalidomide inducers (thalidomide, pomalidomide, lenalidomide) or target degradation inducers using the thalidomide skeleton have binding activity with SALL4 and PLZF, they eventually degrade these proteins and cause teratogenic toxicity. Meanwhile, Kroenke and Lu have reported on the antitumor effect of lenalidomide (cell proliferation inhibitory effect in multiple myeloma), and have revealed that the antitumor effect is expressed through a series of mechanisms from substrate recognition by cereblon of Ikaros (IKZF1) and Aiolos (IKZF3), which are essential factors for the differentiation of B cells and T cells, to ubiquitination and degradation by the proteasome. (Kroenke J, et al., Science 343, 301-305(20014)). In the following Examples, therefore, functional group modification of the thalidomide skeleton was investigated with the aim of developing a non-teratogenic thalidomide-based drug, a target degradation inducer utilizing the thalidomide skeleton. EXAMPLES
[0171] Among thalidomide derivatives (including thalidomide, pomalidomide, and lenalidomide), the glutarimide ring is primarily used to bind to cereblon (see Nature 2014, 512, 49-53, Nature Structural & Molecular Biology 2014, 21, 803-809). Therefore, we substituted the 4th to 7th positions of the benzene ring of the phthalimide ring with various functional groups and investigated their binding ability to IKZF1, IKZF3, SALL4, and PLZF, as well as the degree of degradation of IKZF1, IKZF3, SALL4, and PLZF in cells due to this binding ability. In addition, as is clear from the results of the above examples, it is possible to impart a function of inducing degradation of a target protein by binding a function (target protein binder) that binds to a specific protein via a linker at position 4. In this example, BRD was selected as the degradation target protein, and JQ-1 was used as the target protein binder. Furthermore, since this linker and target protein binder portion are considered to have a high steric exclusion volume effect, the binding ability to IKZF1, IKZF3, SALL4, and PLZF, and the degree of degradation of these in cells were similarly examined.
[0172] The binding ability of thalidomide, pomalidomide, and lenalidomide to each molecule and the degree of degradation in cells were evaluated. The binding ability to each molecule was analyzed by biochemical interaction (AlphaScreen method), and the degradation ability of each molecule in cells was evaluated by the following method.
[0173] (1) Selection of cell tumor H929 cells were used for IKZF1, IKZF3, and BRD (BRD2, BRD3, BRD4), and Huh7 cells were used for SALL4 and PLZF. (Culture conditions) 50-60 x 10 cells of each type 4 The incubation temperature was 37°C for 16 to 20 hours, and the carbon dioxide concentration was 5%. (Addition of Compounds) 1 μL of compound solution adjusted to 10 mM using DMSO as a solvent was added, and the final compound concentration in the medium was 10 μM. In this state, the cells were incubated at 37°C for 16 to 20 hours under a carbon dioxide concentration of 5%. At the same time, cells to which the same amount of DMSO solvent not dissolving the compound was added were prepared as an evaluation control.
[0174] (Cell recovery and preparation of samples for Western blotting evaluation) 1)H929 cells H929 cell suspension was collected in a random 1.5 mL tube. H929 cells are floating cells, so there is no need to detach them. To make the number of cells in each collected sample uniform, they were quantified using the BCA method and diluted to match the lowest concentration sample. SDS sample buffer containing mercaptoethanol was added to the diluted H929 cell suspension and heated at 98°C for 5 minutes. 2)Huh cells The medium of the HuH7 cell solution was aspirated. HuH7 cells are adherent cells, so they stick to the bottom of the plate. 100 μL of SDS sample buffer containing mercaptoethanol was added to each 24-well plate. HuH7 cells were detached by scraping the bottom of the 24-well plate with a wide nozzle tip, and collected in a 1.5 mL tube of your choice. As with H929 cells, the cells were quantified by the BCA method, the cell count was adjusted, and then heated at 98°C for 5 minutes.
[0175] (Quantification of IKZF1, IKZF3, SALL4, and PLZF by Western blotting) The amounts of IKZF1, IKZF3, SALL4, and PLZF remaining in each cell after degradation were quantified. (Quantification of each protein by Western blotting) Detection (chemiluminescence imaging) was performed using Amersham ImageQuant 800 / Cytiva. After detection, the antibody was removed from the membrane using a stripping solution, and the next antibody reaction was carried out. Image data taken with the Amersham ImageQuant 800 was read and analyzed with Quantity One / Bio-Rad software. The bands of the target protein were quantified with Quantity One, and the degree of degradation was evaluated as the percentage of the number of molecules remaining after degradation relative to the number of molecules remaining after the addition of the compound, with the remaining amount of each molecule after the addition of DMSO as an evaluation control without the compound being set at 100%. The antibodies used for detection are as shown in Table 3 below. Anti-CRBN-Ab was used to check whether the expression level of CRBN in cells increased or decreased due to the addition of the compounds, and no significant changes were observed after the addition of the compounds, confirming that the expression was uniform. Each antibody is commercially available from Thermo Fisher, SANTA Cruz, Cell Signaling, and MBL.
[0176] [Table 3]
[0177] (Synthesis of 7-CF3-pomalidomide) It was synthesized by the following procedure. 30 mg (0.1 mmol) of ((trifluoromethyl)sulfonyl)benzene, 10 mg (0.06 mmol) of copper(I) iodide, and 10 mg (0.1 mmol) of potassium t-butoxide were dissolved in 1 mL of dry N,N-dimethylformamide and stirred at room temperature for 30 minutes. Then, 7 mg (0.02 mmol) of 7-Br-pomalidomide was added. After 12 hours, the solvent was removed under reduced pressure, and the mixture was redissolved in ethyl acetate and purified by silica gel column chromatography. 2.0 mg of 4-amino-2-(2,6-dioxopiperidin-3-yl)-7-trifluoromethylisoindoline-1,3-dione was obtained in a yield of 30%. 1 H-NMR(500 MHz, CDCl3) δ 2.11-2.18 ppm (m, 1 H), 2.69-2.95 ppm (m, 3 H), 4.90-4.97 ppm (m, 1 H), 5.67-5.87 ppm (m, 2 H), 5.26 ppm (brs, 2 H), 7.30 (m, 1H), 7.48 (m, 1H), 7.9 (brs, 1H); 19 F-NMR (470 MHz, CDCl3): -121.9. (Synthesis of 5,7-Br-pomalidomide) It was synthesized by the following procedure. Pomalidomide (100 mg, 0.366 mmol) and N-bromosuccinimide (390 mg, 2.2 mmol) were dissolved in acetonitrile (4 mL) and stirred at room temperature for 24 hours. After removing the solvent under reduced pressure, the residue was redissolved in ethyl acetate and purified by silica gel column chromatography. 4-Amino-7-bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was obtained in a yield of 42 mg and 33%. 1 H-NMR(500 MHz, CDCl3) δ 2.11-2.18 ppm (m, 1 H), 2.69-2.95 ppm (m, 3 H), 4.90-4.97 ppm (m, 1 H), 5.67-5.87 ppm (m, 2 H), 5.26 ppm (brs, 2 H), 7.46 (m, 1H), 7.54 (m, 1H), 7.68 (brs, 1H) As a by-product of the above reaction, 4-amino-5,7-bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione was obtained in a yield of 2.1 mg. 1 H-NMR(500 MHz, CDCl3) δ 2.11-2.18 ppm (m, 1 H), 2.69-2.95 ppm (m, 3 H), 4.90-4.97 ppm (m, 1 H), 5.67-5.87 ppm (m, 2 H), 5.26 ppm (brs, 2 H), 8.1 (s, 1H) 7.81 (brs, 1H)
[0178] A similar trend was observed for thalidomide, pomalidomide, and lenalidomide, with degradation of IKZF1 and IKZF3, which brings about an anti-tumor effect in multiple myeloma (see Figure 34). On the other hand, degradation of SALL4 and PLZF, which are the cause of teratogenicity, was also observed at the same time. Furthermore, the increased binding ability of IKZF1, IKZF3, SALL4, and PLZF compounds to CRBN enhanced the degradation of these molecules in cells (see Figure 34).
[0179] As target protein degradation inducers, compounds containing a highly sterically hindered linker and a protein target binder at the 4th position were used to examine the effect of modifications at the 4th position on the binding to each of IKZF1, IKZF3, SALL4, and PLZF, and the resulting effect on the degradation of each of IKZF1, IKZF3, SALL4, and PLZF in expressing cells (see Figure 35). As a hydrogen-substituted amine at the 4th position, a compound was used as a model compound, in which polyethylene glycol was used as a linker and the JQ-1 compound, a BET bromodomain inhibitor that targets BRD, was linked to the linker. This compound can be said to be a highly flexible substitute because JQ-1 is extremely bulky and polyethylene glycol with n=3 is used as a linker. The results are shown in Figure 35. Regarding the biochemical interaction of BRD, the interaction between Flag-GST-BRD4 and biotinylated CRBN was evaluated by the AlphaScreen method, as in IKZF. Regarding the degradation of BRD in cells, the average value of the degradation of BRD2, BRD3, and BRD4 was calculated using the BRD antibodies in Table 3. The remaining amount of each molecule after the addition of DMSO, an evaluation control without any compound, was set as 100%, and the relative ratio of the number of remaining molecules after the addition of the compound was used to evaluate the degree of degradation as the percentage of the number of remaining molecules after degradation. Regardless of whether the basic structure is pomalidomide or lenalidomide, the binding ability to IKZF1, IKZF3, SALL4, and PLZF showed a similar tendency, and surprisingly, when a "linker" or "target binder" was substituted at the 4th position (in this experiment, polyethylene glycol with n=3 was used as the linker, and JQ-1, which targets BRD, was used as the model compound as the target protein binder), it was confirmed that this substituent did not affect the binding ability to IKZF1, IKZF3, SALL4, and PLZF. In addition, a comparison of lenalidomide and 4-fluorinated lenalidomide confirmed that modifications at positions other than the 4th position of the benzene ring have a dominant effect on the binding tendency and decomposition tendency of each molecule, compared with the effect of modifications at the 4th position. In other words, when a protein binder (protein targeting function) is added to the 4th position via a linker, the target protein binder can be selected arbitrarily. In detail, functional group modification at the 6- and 7-positions of the benzene ring of pomalidomide and lenalidomide is important for suppressing the binding ability to SALL4 and PLZF. We confirmed that modification at the 5-position also suppresses the binding ability to SALL4 and PLZF.
[0180] The effect of substituents was confirmed mainly at the 5th and 6th positions of the pomalidomide skeleton (see Figure 36). As for the results of 6-position modification, when halogen substitution was performed, the binding to SALL4 and PLZF was clearly reduced in all cases, F, Cl, and Br, compared to pomalidomide, and the effect was also higher as the van der Waals radius increased. In terms of the degree of degradation in cells, the effect was also greater for Cl and Br. On the other hand, the binding ability to IKZF1 and IKZF3 was not completely lost, confirming that the antitumor effect against multiple myeloma was maintained while the teratogenic toxicity was attenuated. On the other hand, regarding the effect of halogen modification at the 7th position, F's binding ability to IKZF1 and IKZF3 is greatly reduced, while its binding ability to SALL4 and PLZF is also lost. As a result, when this is used as the core of a target degradation inducer, not only is teratogenic toxicity attenuated, but the degradation of IKZF1 and 3 is also suppressed, so it can be used as a neutral (no biological effect) target degradation inducer that can recruit only cereblon by utilizing only the targeting ability of the target protein binder (molecular glue function). On the other hand, when halogen substitution with Cl or Br, which has a large van der Waals radius, is performed, Cl increases the binding ability to both SALL4 and PLZF compared to F substitution, and the degradation in cells is also increased. Substitution with Br, which has a larger van der Waals radius than Cl, further suppresses the degradation of SALL4 and PLZF. Furthermore, when the substituent is changed to a methyl trifluoride group, the binding to SALL4 and PLZF is greatly weakened, and the degradation of SALL4 and PLZF is also suppressed. It can also be seen that the binding to IKZF1 and IKZF3 is significantly suppressed. This tendency is clearly different from that in the case of 6-position modification. In addition, a comparison can be made between pomalidomide-based and lenalidomide-based compounds substituted with fluorine at the 7th position, and it can be seen that both show almost the same tendency. When Br substitution was performed at positions 5 and 7, the binding ability to IKZF1, IKZF3, SALL4, and PLZF was lost compared to position 7 alone, and degradation in cells was almost completely suppressed. When a hydroxyl group was substituted at the 7th position, as with the 3-fluoromethyl group substitution, the molecular glue function was extremely high, with the binding ability to IKZF1, IKZF3, SALL4, and PLZF being lost and degradation within the cells being almost completely suppressed, confirming that it is ideal as the core of a target degradation inducer that has linker and target binder functions at the 4th position.
[0181] The effect of substituents was confirmed mainly at the 6th and 7th positions of the lenalimid skeleton (see Figure 37). It was confirmed that, when halogen substitution was performed at the 6-position, the binding ability to SALL4 and PLZF was significantly decreased while the binding ability to IKZF1 and IKZF3 was maintained, and the teratogenic toxicity was significantly reduced. This tendency was similar to that of the pomalidomide skeleton. It was also found that the larger the van der Waals radius of the functional group, the lower the binding ability to SALL4 and PLZF, and as a result, the greater the effect of suppressing degradation in cells. The tendency was similar to that of the pomalidomide skeleton. In particular, it was confirmed that the effect was greater when substituted with bulky functional groups such as trifluoromethyl and trifluoromethoxy.
[0182] In the results shown in Figure 36, a 7-position modified pomalidomide scaffold that does not induce degradation of IKZF1, IKZF3, SALL4, or PLZF was used to synthesize a 7-position modified pomalidomide-linker-JQ-1 derivative using a chemical reaction similar to that used in Example 12, and the biochemical interactions (AlphaScreen method) of IKZF1, IKZF3, SALL4, PLZF, BRD4, and CRBN, as well as the degree of degradation of each protein in cells, were evaluated (see Figure 38). Both the 7-fluorinated pomalidomide linker target binder (JQ-1) and the 7-trifluoro pomalidomide linker target binder (JQ-1) had low binding ability to SALL4 and PLZF, and as a result, it was confirmed that the degree of degradation of SALL4 and PLZF in cells was significantly reduced compared to the pomalidomide linker target binder (JQ-1). This tendency was confirmed to be due to the inheritance of the binding ability of the basic structure to IKZF1, IKZF3, SALL4, and PLZF before the substitution of the "linker" and "target binder" at the 4th position. As a result, when these compounds are used as CRBN binders, it is possible to create targeted protein degradation inducers that only induce degradation of the target protein and whose other properties are biologically neutral.
[0183] (Overall review) With regard to blood cancer, since the drug targets are both the neo-substrates IKZF1 / 3, CK1α and the target proteins BRD2 / 3 / 4, compounds with high decomposition ability for IKZF1 / 3 are thought to have a high therapeutic effect. On the other hand, in cancer types other than blood cancer, IKZF1 / 3 and CK1α are not targets of drug efficacy, and are instead thought to lead to side effects in the blood system. More specifically, IKZF1 / 3 is involved in the proliferation of blood cancers (especially multiple myeloma), but is a protein expressed in blood cells (especially white blood cells), and is not thought to be significantly involved in cancers other than blood cancer. On the other hand, IKZF1 / 3 is an extremely important transcription factor in the differentiation and function of hematopoietic stem cells into white blood cells (especially lymphocytes such as T cells and B cells). In fact, IKZF1 / 3 knockout mice become immunodeficient and lack T cells and B cells. In addition, it has been reported that the degradation of IKZF1 and IKZF3 by administration of lenalidomide in mice causes a decrease in white blood cells and platelets. In addition, there have been reports of side effects such as a decrease in white blood cells associated with the administration of thalidomide derivatives to patients. In other words, significant degradation of IKZF1 / 3 in cancer types other than blood cancer does not contribute to drug efficacy and is thought to lead to side effects.
[0184] It has been genetically shown that heterozygous SALL4 mutations can cause a congenital disease called Okihiro syndrome (Duane-radial ray syndrome). In addition, this disease is teratogenic in various parts of the body, including the hands and feet, and its phenotype is very similar to thalidomide fetusopathy. In addition, considering that thalidomide and thalidomide derivatives have a high ability to induce the degradation of SALL4, and that Okihiro syndrome can occur even in heterozygous SALL4 mutations, it is highly likely that the teratogenicity is caused by the degradation of SALL4. It has also been confirmed that administration of thalidomide to rabbits reduces SALL4 in the fetus. It has been reported that PLZF causes teratogenicity in humans and mice through mutation. We have also reported that PLZF is degraded in a chicken embryo system in which SALL4 is not degraded. Furthermore, we have experimentally demonstrated that overexpression of PLZF in chicken embryos reduces the teratogenicity of thalidomide. In other words, it is thought that severe teratogenicity is caused by the marked degradation of both SALL4 and PLZF in humans. It has also been reported that double knockout of SALL4 and PLZF in mice results in a more pronounced teratogenic phenotype, which closely resembles thalidomide embryopathy. Thus, reducing the degradation of SALL4 and PLZF would reduce teratogenicity.
[0185] Based on the above findings and the results of the above examples, the following was confirmed. Compared to the existing drug lenalidomide, F-Len has higher activity against multiple myeloma and significantly higher activity against 5qMDS. On the other hand, its ability to induce degradation of SALL4 and PLZF is lower than that of lenalidomide. In other words, F-Len is a thalidomide derivative with reduced teratogenicity and higher pharmacological activity than the existing drug lenalidomide. Compared with the existing drug lenalidomide, Cl-Len has weaker activity against multiple myeloma and 5qMDS, but does not induce the degradation of SALL4 or PLZF. In other words, Cl-Len has a weaker pharmacological effect than the existing drug lenalidomide, but has significantly reduced teratogenicity. Br-Len has a weaker pharmacological effect against multiple myeloma than the existing drug lenalidomide, and does not induce the degradation of SALL4 or PLZF. In other words, Br-Len has a weaker pharmacological effect than the existing drug lenalidomide, but has a significantly reduced teratogenicity. F3C-Len does not induce the degradation of representative neo-substrates such as IKZF1 / 3 and CK1α, which are targets of drug efficacy against blood cancer, and SALL4 and PLZF, which are involved in teratogenicity. However, it can induce high protein degradation via CRBN. Therefore, F3C-Len is expected to be applied to PROTACs with few side effects for various types of cancer. PROTACs using F-Len are as effective against blood cancers as existing PROTACs, and have reduced ability to induce degradation of SALL4 and PLZF. In other words, F-Len-PROTACs are highly effective against blood cancers and have reduced teratogenicity. Furthermore, they are effective against other types of cancer. Although the effect of Cl-Len-based PROTACs on blood cancers is weaker than that of existing PROTACs, they do not induce the degradation of SALL4 or PLZF. In other words, Cl-Len-PROTACs are effective against blood cancers and have significantly reduced teratogenicity. Furthermore, they are effective against other types of cancer. F3C-LenPROTAC appears to be effective against a variety of cancer types and is free of both teratogenic and hematological side effects. Based on the similar chemical structure and chemical properties to F3C-Len-PROTAC and the results of the examples, F3CO-Len-PROTAC is considered to be effective against various types of cancer and has no side effects in both teratogenicity and the blood system. Based on the results of the examples, Br-Len-PROTAC, like F3C-Len-PROTAC, is considered to be effective against various types of cancer and has no side effects in both teratogenicity and the blood system.
[0186] Based on the above findings and the results of Example 18, the following was confirmed. 1) It was confirmed that the functional groups of thalidomide derivatives (especially positions 6 and 7) have a large effect on teratogenicity. 2) The stronger the biochemical binding of thalidomide derivatives to IKZF1, IKZF3, SALL4, and PLZF, the higher their ability to degrade IKZF1, IKZF3, SALL4, and PL in cells. 3) When a linker was extended to the 4th position of a thalidomide derivative (especially the amino group at the 4th position) and a target molecule (POI: protein of interest, bulky) was bound to it, it was confirmed that the linker and the POI had almost no effect on the degradation by SALL4 and PLZF. In other words, by binding a linker to the 4th position and then binding a POI to the linker, the decomposition ability of SALL4 and PLZF was not inhibited or improved. In addition, the modification state of the 6th and 7th positions of the thalidomide derivative is extremely important for the decomposition ability by SALL4 and PLZF. 4) The binding ability to SALL4 and PLZF was weakened by the substitution of the 6-position modification group. This suggests the possibility of the effect of steric hindrance of the modification group. On the other hand, the binding ability to IKZF1 and 3 remained. 5) Modification at position 7 weakens the binding ability to IKZF1,3, SALL4, and PLZF. 6) Functional groups with large van der Waals radii at the 7th position reduce the binding selectivity, especially to SALL4 and PLZF. 7) Even without the steric hindrance effect, highly electronegative functional groups (F) or functional groups that form hydrogen bonds (OH) strongly inhibit the binding of SALL4 and PLZF. This is because when thalidomide derivatives interact with CRBN, His359 is structurally located nearby, and they interact with the imidazole group of His, reducing the space available for SALL4 and PLZF to enter. [Industrial Applicability]
[0187] It is possible to provide a novel target protein degradation-inducing compound and a cancer therapeutic composition containing said compound, as well as a cancer therapeutic composition with reduced teratogenicity.
[0188] The present invention is as follows. 1. A target protein degradation inducer compound having the following composition: "Cerebron binder" - "linker" - "target protein binder", Here, the cerebron binder is a target protein degradation-inducing compound selected from any one of compounds represented by the following general formula (10), their salts, or their solvates. [ka] (wherein X is CH2 or C=O, and R10 is hydrogen, a functional group, an atom, or NR L1 R L2 And R L1 and R L2 is hydrogen, a functional group, or an atom, but any one of them is a functional group or an atom, and R11 is hydrogen, F, Br, Cl, CH3, OCH 3、 I, CF3 or OCF3, and R12 is hydrogen, F, Br, CF3, I, OH, Cl, CH3, OCF3 or OCH3. 2. The target protein decomposition-inducing compound described in the preceding item 1, wherein the target protein binder is JQ-1 or Birabresib. 3. The target protein decomposition inducer compound according to item 1 or 2 above, wherein X in the general formula (10) is CH2, R11 is CF3, and R12 is hydrogen. 4. The target protein decomposition inducer compound according to item 1 or 2 above, wherein X in general formula (10) is CH2, R11 is F, and R12 is hydrogen. 5. The target protein decomposition inducer compound according to item 1 or 2 above, wherein X in general formula (10) is CH2, R11 is Cl, and R12 is hydrogen. 6. A target protein decomposition inducer compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (7), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. and the target protein binder is Birabresib or JQ-1. Targeted protein degradation-inducing compounds. 7. A target protein decomposition inducer compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (3), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. and the target protein binder is Birabresib or JQ-1. Targeted protein degradation-inducing compounds. 8. A target protein decomposition inducer compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (8), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. and the target protein binder is Birabresib or JQ-1. Targeted protein degradation-inducing compounds. 9. A target protein decomposition inducer compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (6), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. and the target protein binder is Birabresib or JQ-1. Targeted protein degradation-inducing compounds. 10. A target protein decomposition inducer compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (5), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. and the target protein binder is Birabresib or JQ-1. Targeted protein degradation-inducing compounds. 11. A target protein decomposition inducer compound according to the preceding item 1 or 2, having the following configuration: The cerebron binder is selected from any one of a compound represented by the following general formula (4), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 is a hydrogen atom, a functional group, or an atom, but one of them is a functional group or an atom. And the target protein degradation-inducing compound, wherein the target protein binder is Birabresib or JQ-1. 12. The target protein degradation-inducing compound according to the preceding item 1 or 2, wherein the protein degradation ability of SALL4 or PLZF is reduced. 13. The target protein degradation inducer compound described in the preceding item 1 or 2, which has reduced teratogenicity. 14. A composition for treating cancer, comprising one or more target protein degradation-inducing compounds according to the preceding paragraph 1 or 2. 15. A composition for treating cancer, comprising a compound represented by the following general formula (1), a salt thereof, or a solvate thereof: [ka] (where R1 is hydrogen, F, Br, Cl, CH3, OCH 3、 I, CF3 or OCF3, R L1 and R L2 are each independently a hydrogen atom, a functional group, or an atom. 16. The composition for cancer treatment according to the above item 15, wherein the compound represented by the following general formula (1) is a compound represented by general formula (7), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently a hydrogen atom, a functional group, or an atom. 17. The composition for cancer treatment according to the above item 15, wherein the compound represented by the following general formula (1) is a compound represented by general formula (8), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently a hydrogen atom, a functional group, or an atom. 18. The composition for cancer treatment according to the above item 15, wherein the compound represented by the following general formula (1) is a compound represented by general formula (6), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently a hydrogen atom, a functional group, or an atom. 19. The composition for cancer treatment according to the above item 15, wherein the compound represented by the following general formula (1) is a compound represented by general formula (3), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently a hydrogen atom, a functional group, or an atom. 20. The composition for cancer treatment according to the preceding item 15, wherein the compound represented by the following general formula (1) is a compound represented by general formula (5), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently a hydrogen atom, a functional group, or an atom. 21. A therapeutic agent for chromosome 5-deficient myelodysplastic syndrome, comprising a compound represented by the following general formula (5), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2are each independently a hydrogen atom, a functional group, or an atom. 22. A therapeutic agent for chromosome 5-deficient myelodysplastic syndrome, comprising a compound represented by the following general formula (3), a salt thereof, or a solvate thereof: [ka] (where R L1 and R L2 are each independently a hydrogen atom, a functional group, or an atom.
Claims
[Claim 1] The invention described in the specification
Citation Information
Patent Citations
Preparation process of isoindoline-1,3-dione compounds
JP2015524811A
Imido-based proteolytic modulators and related methods of use
JP2017513862A
Condensed 1,4-diazepines as BET proteolytic agents
JP2019526616A
Fluorine-containing thalidomide derivative and pharmaceutical composition and method for producing the same
JP2021147365A
Bromodomain targeting degronimers for target protein degradation
WO2017197056A1
